breast ductal carcinoma in situ: A carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.
Carcinoma in situ of breast, other/unspecified
DOID EFO Endpoint Browser PheWeb
CD2_INSITU_BREAST_NOS
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleonly females |
293145 |
2. Check conditionsNone |
293145 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
505 |
4. Check minimum number of eventsNone |
505 |
5. Include endpointsNone |
505 |
6. Filter based on genotype QC (FinnGen only) |
485 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Carcinoma in situ of breast, other/unspecified
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 485 | 485 | - |
| Unadjusted period prevalence (%) | 0.17 | 0.17 | - |
| Median age at first event (years) | 58.85 | 58.85 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 505
- Matched controls
- 5050
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D05.1
ICD-10 Finland
Intraductal carcinoma in situ
74.6
307.7
274
79
8500/2-C50.9
ICD-O-3
Intraductal carcinoma, noninfiltrating, NOS, of breast, NOS
75.6
307.7
187
39
D05.9
ICD-10 Finland
Carcinoma in situ of breast, unspecified
+∞
307.7
361
*
PJA12
NOMESCO Finland
Sentinel node biopsy
9.4
139.5
242
451
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
10.5
130.7
180
253
HAB40
NOMESCO Finland
Wedge excision of mammary gland
9.8
130.2
195
304
HAC20
NOMESCO Finland
Total mastectomy
11.4
126.1
156
190
HAE20
NOMESCO Finland
Reconstruction of areola and mamilla using graft or flap
22.2
105.3
81
43
HAE10
NOMESCO Finland
Reconstruction of breast using graft or flap
19.4
104.4
86
53
C50.99
ICD-10 Finland
Breast, unspecified
11.1
102.3
123
142
D05.7
ICD-10 Finland
Other carcinoma in situ of breast
+∞
99.3
92
*
TQW20
NOMESCO Finland
Tatoe
22.8
93.9
71
36
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
7.3
78.1
138
248
2330A
ICD-9 Finland
Carcinoma in situ of breast and genito-urinary system, Breast
+∞
70.5
66
*
HA1AA
NOMESCO Finland
X-ray mammography
5.3
66.2
180
478
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
5.5
62.6
155
378
HAC15
NOMESCO Finland
Subcutaneous mastectomy with excision of mamilla
21.8
58.0
44
22
HA6AA
NOMESCO Finland
Extra corporeal mammography of operated mammary gland
6.8
57.3
101
178
Z85.3
ICD-10 Finland
Personal history of malignant neoplasm of breast
10.4
57.0
67
73
C50
ICD-10 Finland
Malignant neoplasm of breast
8.1
55.9
82
118
115
Kela drug reimbursment
Breast cancer
4.5
53.0
174
527
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
5.0
49.0
129
326
8503/2-C50.9
ICD-O-3
Noninfiltrating intraductal papillary adenocarcinoma of breast, NOS
252.4
45.8
46
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
5.8
40.9
82
162
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
4.9
37.2
92
218
C50.90
ICD-10 Finland
Malignant tumor in other or unspecified location in mammary gland without histology
8.6
35.9
48
61
9703
FHL
Breast resection
11.3
35.3
38
36
HAE99
NOMESCO Finland
Other reconstruction of breast
14.1
35.1
33
25
HAB00
NOMESCO Finland
Excision of lesion of mammary gland
6.2
34.7
64
116
D05.0
ICD-10 Finland
Lobular carcinoma in situ
82.1
34.3
38
5
ZZR10
NOMESCO Finland
Flap of skin and muscle
14.2
34.2
32
24
HAB99
NOMESCO Finland
Other partial excision of mammary gland
6.2
31.6
57
101
N63
ICD-10 Finland
Unspecified lump in breast
4.0
30.3
98
284
HAD30
NOMESCO Finland
Reduction mammoplasty with transposition of areola
5.5
29.5
61
123
HA4AT
NOMESCO Finland
Labeling mammary gland pathology with ultrasound guidance
5.3
27.2
58
120
Z31.5
ICD-10 Finland
Genetic counselling
4.7
26.5
67
160
WX702
NOMESCO Finland
Supraglottic ventilation device
4.3
24.9
71
186
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.8
24.7
177
821
L02BA01
ATC
tamoxifen; oral
4.0
24.2
76
214
C50.91
ICD-10 Finland
Malignant tumor in another specified localization in ductal mammary gland
6.5
24.1
41
68
C50.49
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, other or undeterminated histology
6.4
23.3
40
67
C50.4
ICD-10 Finland
Malignant neoplasm: Upper-outer quadrant of breast
8.6
22.9
30
37
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
4.0
22.2
70
197
N60.9
ICD-10 Finland
Benign mammary dysplasia, unspecified
20.0
21.5
32
17
9707
FHL
Ablation of mammae and removal of axillary lymph nodes
22.7
21.1
30
14
C50.11
ICD-10 Finland
Malignant tumor of the central part of the mammary gland,ductal tumor
6.5
20.9
35
57
PJD42
NOMESCO Finland
Excision of axillary lymph nodes
9.1
20.8
26
30
WZC00
NOMESCO Finland
Treatment plan or consultation
2.4
20.3
245
1427
HAB50
NOMESCO Finland
Partial excision of mammary gland with reconstructive operation
5.0
20.3
46
100
L02BG04
ATC
letrozole; oral
3.0
20.1
101
383
ZX080
NOMESCO Finland
Image guided radiotherapy
5.6
19.5
38
72
WX402
NOMESCO Finland
General anaesthesia
2.5
18.4
157
777
C50.81
ICD-10 Finland
Overall malignant tumor of the mammary gland, ductal tumor
5.8
18.1
34
62
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
6.3
18.0
31
52
D05
ICD-10 Finland
Carcinoma in situ of breast
186.3
17.6
18
*
Z80.3
ICD-10 Finland
Family history of malignant neoplasm of breast
5.5
17.5
35
68
XX3DW
NOMESCO Finland
Time consuming IT work
2.8
15.6
93
383
X76
ICPC
Malignant neoplasm breast female
4.6
15.5
38
88
HA1AA, ,
SPAT
4.5
15.3
38
89
HA1AE, ,
SPAT
4.4
15.1
39
94
WF003
NOMESCO Finland
Adjuvant radiotherapy
4.5
15.1
38
90
ZXE30
NOMESCO Finland
More than five and less than seven hours
4.3
15.0
40
99
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
3.8
14.4
46
130
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
4.1
13.8
39
101
THW99
NOMESCO Finland
Other minor procedure in surgery of mammary gland
4.2
13.7
38
97
A04AA02
ATC
granisetron; systemic, transdermal
2.9
13.0
64
237
H02AB02
ATC
dexamethasone; systemic
2.4
12.7
101
476
PJ5YQ, ,
NOMESCO Finland
133.2
12.5
13
*
9702
FHL
Breast exploration and possible tumor removal
4.9
12.0
27
58
C50.40
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, no histological veryfication
3.8
11.7
37
104
8500/2-C50.4
ICD-O-3
Intraductal carcinoma, noninfiltrating, NOS, of upper-outer quadrant of breast
66.5
11.7
13
*
HAD20
NOMESCO Finland
Liposuction of breast
66.5
11.7
13
*
HAD99
NOMESCO Finland
Other plastic operation on breast
9.6
11.6
23
25
ZZF00
NOMESCO Finland
Graft of adipose tissue
10.4
11.6
22
22
ZZQ10
NOMESCO Finland
Free microvascular graft of skin and muscle
15.5
11.4
18
12
D48.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Breast
4.5
11.4
28
65
TQB05
NOMESCO Finland
Puncture of skin of trunk
9.9
11.4
22
23
9706
FHL
Ablation mammae, includes axillary exploration
35.9
11.3
14
*
5702
FHL
Local lymph node removal (eg armpit, groin)
17.5
11.3
17
10
C50.51
ICD-10 Finland
Malignant tumor of the lower outer quadrant of the mammary gland, ductal tumor
4.3
11.0
29
71
1744A
ICD-9 Finland
Malignant neoplasm of female breast, Upper-outer quadrant
18.3
10.8
16
9
HA3ST
NOMESCO Finland
Removal of lesion of breast with radiological guidance
14.6
10.5
17
12
X21
ICPC
Breast sympt/compl female other
4.1
10.0
28
72
QBA00
NOMESCO Finland
Puncture of skin of trunk
26.6
9.9
13
5
HA1AT
NOMESCO Finland
Biopsy of mammary glands with ultrasound guidance
3.6
9.8
32
92
HAE00
NOMESCO Finland
Reconstruction of breast using prosthesis
13.7
9.7
16
12
HAE05
NOMESCO Finland
Reconstruction of breast using soft tissue and prosthesis
9.4
9.6
19
21
HAD60
NOMESCO Finland
Replacement of prosthetic implant in breast
30.7
9.4
12
*
HA4ST
NOMESCO Finland
Labeling mammary gland pathology with sterotactic guidance
12.7
9.4
16
13
Z42.1
ICD-10 Finland
Follow-up care involving plastic surgery of breast
11.0
9.3
17
16
HAD40
NOMESCO Finland
Mastopexy
11.0
9.3
17
16
HA1CG
NOMESCO Finland
Extensive MRI examination of mammary gland with high intensity magnet
4.1
9.2
25
63
NK6AN
NOMESCO Finland
Total body bone isotope imaging
4.0
9.1
26
68
C50.9
ICD-10 Finland
Malignant neoplasm: Breast, unspecified
7.9
8.7
19
25
C50.31
ICD-10 Finland
Malignant tumor of the lower inner quadrant of the mammary gland, ductal tumor
4.5
8.7
21
48
C50.19
ICD-10 Finland
Malignant tumor of the central part of the mammary gland, other or undeterminated histology
9.2
8.6
17
19
8509/2-C50.9
ICD-O-3
Solid papillary carcinoma in situ of breast, NOS
+∞
8.4
8
*
A04AD12
ATC
aprepitant; systemic
3.5
7.9
27
80
A03FA01
ATC
metoclopramide; systemic, rectal
1.8
7.8
155
1003
HAA10
NOMESCO Finland
Biopsy of mammary gland
6.9
7.7
18
27
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
2.5
7.6
48
202
8520/2-C50.9
ICD-O-3
Lobular carcinoma in situ, NOS, of breast, NOS
25.4
7.6
10
*
L02BG06
ATC
exemestane; oral
3.3
7.4
27
84
N64.9
ICD-10 Finland
Disorder of breast, unspecified
7.0
7.3
17
25
HWD00
NOMESCO Finland
Reoperation for deep haemorrhage in surgery of mammary gland
7.0
7.3
17
25
ZXE00
NOMESCO Finland
One hour or less
1.7
7.2
211
1515
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
2.9
7.1
33
118
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
2.2
7.0
63
311
C50.10
ICD-10 Finland
Malignant tumor of the central part of the mammary gland, no histological veryfication
14.0
6.9
11
8
X19
ICPC
Breast lump/mass female
4.2
6.9
18
44
C50.39
ICD-10 Finland
Malignant tumor of the lower inner quadrant of the mammary gland, other or undeterminated histology
11.1
6.8
12
11
L03AA13
ATC
pegfilgrastim; parenteral
2.4
6.8
45
194
D24
ICD-10 Finland
Benign neoplasm of breast
3.3
6.8
25
78
9719
FHL
Other measure in this category
40.6
6.8
8
*
WX408
NOMESCO Finland
General anesthesy, balanced
1.7
6.8
141
920
HA1DG
NOMESCO Finland
Very extensive MRI examination of mammary gland with high intensity magnet
5.6
6.7
18
33
JN4BD
NOMESCO Finland
Extensive body CT
2.1
6.5
63
319
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.6
6.5
251
1918
1749X
ICD-9 Finland
Malignant neoplasm of female breast, Breast (female), unspecified
18.3
6.3
9
5
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
3.5
6.2
21
62
C50.29
ICD-10 Finland
Malignant tumor of the upper inner quadrant of the mammary gland, other or undeterminated histology
6.4
6.2
15
24
C50.89
ICD-10 Finland
Overall malignant tumor of the mammary gland, other or undeterminated histology
6.4
6.2
15
24
ZXE10
NOMESCO Finland
More than one and less than three hours
1.6
6.2
201
1467
HAC10
NOMESCO Finland
Subcutaneous mastectomy with preservation of mamilla
12.7
6.1
10
8
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Intraductal carcinoma in situ
D05.1 [45576374]
D05.1 [45576374]
2.8e+00
4.0e+00
—
1.0e+50
1.0e+50
5.7e+00
4.7e+00
cases:5.39%
controls:0.36%
cases:6.99%
controls:0.14%
—
—
cases:4.99%
controls:0.00%
cases:17.80%
controls:0.00%
cases:32.38%
controls:0.16%
cases:26.46%
controls:0.34%
27
18
474
4992
35
7
466
5003
—
25
0
476
5010
89
0
411
5004
159
8
332
4907
118
15
328
4446
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
9.0e-01
3.6e+00
6.0e+00
1.0e+50
4.4e+00
9.1e-01
6.9e-01
cases:10.38%
controls:4.49%
cases:36.13%
controls:1.46%
cases:41.32%
controls:0.18%
cases:1.20%
controls:0.00%
cases:9.00%
controls:0.12%
cases:2.24%
controls:0.92%
cases:8.97%
controls:4.73%
52
225
449
4785
181
73
320
4937
207
9
294
5001
6
0
495
5010
45
6
455
4998
11
45
480
4870
40
211
406
4250
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
4.2e-01
1.7e+00
3.1e+00
—
4.4e+00
2.8e+00
2.6e+00
cases:4.79%
controls:3.21%
cases:5.59%
controls:1.10%
cases:4.59%
controls:0.22%
—
—
cases:8.80%
controls:0.12%
cases:15.89%
controls:1.12%
cases:26.23%
controls:2.60%
24
161
477
4849
28
55
473
4955
23
11
478
4999
—
44
6
456
4998
78
55
413
4860
117
116
329
4345
General Surgery
2 [38004447]
2 [38004447]
2.5e-01
1.9e+00
4.0e+00
1.0e+50
4.5e+00
2.5e+00
1.2e+00
cases:22.95%
controls:18.80%
cases:27.54%
controls:5.41%
cases:25.95%
controls:0.66%
cases:72.26%
controls:0.00%
cases:43.00%
controls:0.82%
cases:38.90%
controls:5.01%
cases:38.34%
controls:15.47%
115
942
386
4068
138
271
363
4739
130
33
371
4977
362
0
139
5010
215
41
285
4963
191
246
300
4669
171
690
275
3771
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]
C50.41 [2000501002]
-4.3e-02
1.5e+00
3.0e+00
—
3.6e+00
2.9e+00
2.2e+00
cases:1.40%
controls:1.46%
cases:3.79%
controls:0.88%
cases:4.39%
controls:0.24%
—
—
cases:6.80%
controls:0.20%
cases:12.22%
controls:0.73%
cases:13.23%
controls:1.61%
7
73
494
4937
19
44
482
4966
22
12
479
4998
—
34
10
466
4994
60
36
431
4879
59
72
387
4389
Medical Oncology
90 [38004507]
90 [38004507]
4.6e-01
5.2e-01
2.0e+00
—
3.6e+00
4.1e+00
2.8e+00
cases:6.19%
controls:3.99%
cases:4.99%
controls:3.01%
cases:4.59%
controls:0.68%
—
—
cases:21.60%
controls:0.72%
cases:64.77%
controls:2.85%
cases:45.96%
controls:4.91%
31
200
470
4810
25
151
476
4859
23
34
478
4976
—
108
36
392
4968
318
140
173
4775
205
219
241
4242
Outpatient Visit
OP [9202]
OP [9202]
5.0e-02
4.3e-01
1.5e+00
5.6e+00
2.3e+00
1.5e+00
1.2e+00
cases:66.67%
controls:65.55%
cases:55.29%
controls:44.59%
cases:28.54%
controls:8.52%
cases:48.30%
controls:0.36%
cases:50.20%
controls:8.97%
cases:78.00%
controls:43.62%
cases:89.69%
controls:72.70%
334
3284
167
1726
277
2234
224
2776
143
427
358
4583
242
18
259
4992
251
449
249
4555
383
2144
108
2771
400
3243
46
1218
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
2.6e-01
8.4e-01
2.9e+00
—
4.6e+00
1.1e+00
7.7e-01
cases:8.38%
controls:6.59%
cases:5.39%
controls:2.40%
cases:5.39%
controls:0.32%
—
—
cases:12.20%
controls:0.14%
cases:6.52%
controls:2.36%
cases:16.14%
controls:8.16%
42
330
459
4680
27
120
474
4890
27
16
474
4994
—
61
7
439
4997
32
116
459
4799
72
364
374
4097
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
4.0e-01
1.2e+00
3.2e+00
—
3.8e+00
1.3e+00
7.5e-01
cases:8.98%
controls:6.23%
cases:4.59%
controls:1.48%
cases:4.19%
controls:0.18%
—
—
cases:6.40%
controls:0.16%
cases:4.07%
controls:1.18%
cases:7.62%
controls:3.74%
45
312
456
4698
23
74
478
4936
21
9
480
5001
—
32
8
468
4996
20
58
471
4857
34
167
412
4294
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
4.0e-01
1.4e+00
2.8e+00
—
3.6e+00
1.2e+00
9.9e-01
cases:7.98%
controls:5.51%
cases:4.59%
controls:1.20%
cases:3.19%
controls:0.20%
—
—
cases:5.80%
controls:0.16%
cases:3.26%
controls:1.00%
cases:9.42%
controls:3.72%
40
276
461
4734
23
60
478
4950
16
10
485
5000
—
29
8
471
4996
16
49
475
4866
42
166
404
4295
Malignant neoplasm of breast
C50 [45571518]
C50 [45571518]
5.2e-02
1.6e+00
2.2e+00
—
—
3.3e+00
2.3e+00
cases:1.20%
controls:1.14%
cases:1.80%
controls:0.36%
cases:1.20%
controls:0.14%
—
—
—
—
cases:7.74%
controls:0.31%
cases:7.62%
controls:0.85%
6
57
495
4953
9
18
492
4992
6
7
495
5003
—
—
38
15
453
4900
34
38
412
4423
Intravenous general anesthesia
WX404 [2001310807]
WX404 [2001310807]
2.4e-01
1.5e+00
—
—
4.3e+00
1.9e+00
1.5e+00
cases:3.59%
controls:2.85%
cases:3.39%
controls:0.76%
—
—
—
—
cases:11.00%
controls:0.16%
cases:3.67%
controls:0.59%
cases:5.83%
controls:1.39%
18
143
483
4867
17
38
484
4972
—
—
55
8
445
4996
18
29
473
4886
26
62
420
4399
Breast, unspecified
C50.99 [2000501021]
C50.99 [2000501021]
—
2.0e+00
—
1.0e+50
—
3.5e+00
3.3e+00
—
—
cases:1.80%
controls:0.24%
—
—
cases:1.20%
controls:0.00%
—
—
cases:5.30%
controls:0.16%
cases:10.31%
controls:0.43%
—
9
12
492
4998
—
6
0
495
5010
—
26
8
465
4907
46
19
400
4442
Right side
ZXA00 [2001311346]
ZXA00 [2001311346]
1.3e-01
1.0e+00
3.2e+00
1.0e+50
3.5e+00
1.2e+00
7.6e-01
cases:3.99%
controls:3.51%
cases:1.80%
controls:0.64%
cases:2.40%
controls:0.10%
cases:1.20%
controls:0.00%
cases:4.40%
controls:0.14%
cases:2.65%
controls:0.77%
cases:6.50%
controls:3.14%
20
176
481
4834
9
32
492
4978
12
5
489
5005
6
0
495
5010
22
7
478
4997
13
38
478
4877
29
140
417
4321
Outpatient Hospital
22 [8756]
22 [8756]
4.6e-02
8.2e-01
2.7e+00
—
3.1e+00
1.4e+00
6.4e-01
cases:22.75%
controls:21.96%
cases:14.37%
controls:6.89%
cases:9.78%
controls:0.70%
—
—
cases:18.40%
controls:1.02%
cases:19.14%
controls:5.49%
cases:29.60%
controls:18.16%
114
1100
387
3910
72
345
429
4665
49
35
452
4975
—
92
51
408
4953
94
270
397
4645
132
810
314
3651
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
1.9e-01
6.6e-01
2.9e+00
—
3.5e+00
2.0e+00
6.5e-01
cases:5.19%
controls:4.33%
cases:2.59%
controls:1.36%
cases:2.20%
controls:0.12%
—
—
cases:6.20%
controls:0.20%
cases:6.92%
controls:1.04%
cases:6.73%
controls:3.63%
26
217
475
4793
13
68
488
4942
11
6
490
5004
—
31
10
469
4994
34
51
457
4864
30
162
416
4299
Unspecified lump in breast
N63 [45601743]
N63 [45601743]
1.4e+00
3.8e+00
1.0e+50
1.0e+50
—
2.9e+00
1.3e+00
cases:2.79%
controls:0.68%
cases:8.38%
controls:0.20%
cases:4.59%
controls:0.00%
cases:2.20%
controls:0.00%
—
—
cases:2.24%
controls:0.12%
cases:1.79%
controls:0.49%
14
34
487
4976
42
10
459
5000
23
0
478
5010
11
0
490
5010
—
11
6
480
4909
8
22
438
4439
Ultrasound examination of mammary glands
HA1AE [2001303886]
HA1AE [2001303886]
3.5e-01
2.1e+00
—
1.0e+50
—
3.0e+00
2.9e+00
cases:1.80%
controls:1.28%
cases:3.19%
controls:0.40%
—
—
cases:2.00%
controls:0.00%
—
—
cases:4.48%
controls:0.24%
cases:13.23%
controls:0.81%
9
64
492
4946
16
20
485
4990
—
10
0
491
5010
—
22
12
469
4903
59
36
387
4425
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
1.1e-01
7.8e-01
3.2e+00
1.0e+50
3.3e+00
7.2e-01
5.1e-01
cases:6.19%
controls:5.59%
cases:5.59%
controls:2.65%
cases:6.39%
controls:0.28%
cases:4.59%
controls:0.00%
cases:7.80%
controls:0.30%
cases:4.68%
controls:2.34%
cases:13.23%
controls:8.36%
31
280
470
4730
28
133
473
4877
32
14
469
4996
23
0
478
5010
39
15
461
4989
23
115
468
4800
59
373
387
4088
X-ray mammography
HA1AA [2001303884]
HA1AA [2001303884]
6.3e-01
2.1e+00
—
1.0e+50
—
2.7e+00
3.0e+00
cases:2.99%
controls:1.62%
cases:3.79%
controls:0.50%
—
—
cases:4.39%
controls:0.00%
—
—
cases:6.11%
controls:0.45%
cases:17.26%
controls:1.03%
15
81
486
4929
19
25
482
4985
—
22
0
479
5010
—
30
22
461
4893
77
46
369
4415
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
3.5e-02
7.7e-01
2.8e+00
—
3.6e+00
1.2e+00
4.9e-01
cases:4.19%
controls:4.05%
cases:3.59%
controls:1.70%
cases:3.39%
controls:0.22%
—
—
cases:6.60%
controls:0.20%
cases:4.68%
controls:1.42%
cases:8.74%
controls:5.54%
21
203
480
4807
18
85
483
4925
17
11
484
4999
—
33
10
467
4994
23
70
468
4845
39
247
407
4214
Inpatient Hospital
21 [8717]
21 [8717]
-8.5e-02
5.7e-01
2.3e+00
1.0e+50
2.9e+00
1.1e+00
6.1e-01
cases:26.55%
controls:28.24%
cases:15.37%
controls:9.32%
cases:9.58%
controls:1.06%
cases:27.94%
controls:0.00%
cases:18.40%
controls:1.20%
cases:21.18%
controls:8.30%
cases:36.55%
controls:23.83%
133
1415
368
3595
77
467
424
4543
48
53
453
4957
140
0
361
5010
92
60
408
4944
104
408
387
4507
163
1063
283
3398
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
-3.1e-01
7.9e-02
—
—
3.7e+00
2.5e+00
8.1e-01
cases:2.99%
controls:4.05%
cases:1.60%
controls:1.48%
—
—
—
—
cases:5.40%
controls:0.14%
cases:15.27%
controls:1.42%
cases:10.54%
controls:4.98%
15
203
486
4807
8
74
493
4936
—
—
27
7
473
4997
75
70
416
4845
47
222
399
4239
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
0.0e+00
9.7e-01
2.3e+00
—
3.3e+00
1.0e+00
4.8e-01
cases:2.99%
controls:2.99%
cases:2.99%
controls:1.16%
cases:1.60%
controls:0.16%
—
—
cases:4.80%
controls:0.18%
cases:3.26%
controls:1.22%
cases:6.05%
controls:3.83%
15
150
486
4860
15
58
486
4952
8
8
493
5002
—
24
9
476
4995
16
60
475
4855
27
171
419
4290
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
-1.4e-02
1.5e-01
1.5e+00
3.2e+00
1.4e+00
5.4e-01
2.9e-01
cases:16.57%
controls:16.77%
cases:16.37%
controls:14.43%
cases:11.98%
controls:2.95%
cases:5.39%
controls:0.24%
cases:12.40%
controls:3.38%
cases:23.42%
controls:15.10%
cases:35.43%
controls:29.16%
83
840
418
4170
82
723
419
4287
60
148
441
4862
27
12
474
4998
62
169
438
4835
115
742
376
4173
158
1301
288
3160
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
-1.6e-01
8.0e-02
1.3e+00
3.1e+00
1.2e+00
5.4e-01
3.9e-01
cases:14.77%
controls:16.87%
cases:16.57%
controls:15.49%
cases:10.38%
controls:3.09%
cases:4.79%
controls:0.22%
cases:10.80%
controls:3.48%
cases:25.05%
controls:16.32%
cases:39.69%
controls:30.78%
74
845
427
4165
83
776
418
4234
52
155
449
4855
24
11
477
4999
54
174
446
4830
123
802
368
4113
177
1373
269
3088
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
3.3e-01
2.4e+00
—
1.0e+50
1.0e+50
2.6e+00
1.6e+00
cases:1.80%
controls:1.30%
cases:3.39%
controls:0.32%
—
—
cases:1.20%
controls:0.00%
cases:7.60%
controls:0.00%
cases:2.65%
controls:0.20%
cases:3.81%
controls:0.83%
9
65
492
4945
17
16
484
4994
—
6
0
495
5010
38
0
462
5004
13
10
478
4905
17
37
429
4424
Inpatient Visit
IP [9201]
IP [9201]
1.8e-01
6.3e-01
2.3e+00
1.0e+50
3.6e+00
6.9e-01
5.9e-01
cases:10.18%
controls:8.64%
cases:4.99%
controls:2.71%
cases:1.80%
controls:0.18%
cases:7.78%
controls:0.00%
cases:7.20%
controls:0.22%
cases:4.89%
controls:2.50%
cases:13.00%
controls:7.62%
51
433
450
4577
25
136
476
4874
9
9
492
5001
39
0
462
5010
36
11
464
4993
24
123
467
4792
58
340
388
4121
Wedge excision of mammary gland
HAB40 [2001303928]
HAB40 [2001303928]
1.2e+00
3.6e+00
1.0e+50
1.0e+50
—
2.7e+00
1.3e+00
cases:2.00%
controls:0.60%
cases:3.59%
controls:0.10%
cases:4.39%
controls:0.00%
cases:9.18%
controls:0.00%
—
—
cases:2.44%
controls:0.16%
cases:2.02%
controls:0.58%
10
30
491
4980
18
5
483
5005
22
0
479
5010
46
0
455
5010
—
12
8
479
4907
9
26
437
4435
Cancer Ag 15-3 [Units/volume] in Serum or Plasma
6875-9 [3006588]
6875-9 [3006588]
—
1.6e+00
1.0e+50
1.0e+50
—
3.1e+00
3.2e+00
—
—
cases:1.20%
controls:0.24%
cases:1.60%
controls:0.00%
cases:1.40%
controls:0.00%
—
—
cases:4.68%
controls:0.22%
cases:9.64%
controls:0.43%
—
6
12
495
4998
8
0
493
5010
7
0
494
5010
—
23
11
468
4904
43
19
403
4442
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-7.5e-02
1.1e-01
1.4e+00
3.3e+00
1.3e+00
3.8e-01
1.9e-02
cases:19.36%
controls:20.56%
cases:18.36%
controls:16.81%
cases:11.98%
controls:3.35%
cases:5.99%
controls:0.24%
cases:12.60%
controls:3.86%
cases:23.42%
controls:17.33%
cases:33.63%
controls:33.20%
97
1030
404
3980
92
842
409
4168
60
168
441
4842
30
12
471
4998
63
193
437
4811
115
852
376
4063
150
1481
296
2980
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
-1.3e-01
1.4e-02
1.3e+00
3.3e+00
1.2e+00
3.6e-01
1.5e-01
cases:25.15%
controls:27.60%
cases:24.55%
controls:24.29%
cases:15.57%
controls:4.93%
cases:6.99%
controls:0.28%
cases:16.60%
controls:5.50%
cases:32.99%
controls:25.51%
cases:48.21%
controls:44.36%
126
1383
375
3627
123
1217
378
3793
78
247
423
4763
35
14
466
4996
83
275
417
4729
162
1254
329
3661
215
1979
231
2482
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
-1.4e-01
1.2e-02
1.3e+00
3.3e+00
1.2e+00
3.6e-01
1.5e-01
cases:24.95%
controls:27.74%
cases:24.55%
controls:24.33%
cases:15.57%
controls:4.99%
cases:6.99%
controls:0.28%
cases:16.60%
controls:5.54%
cases:32.99%
controls:25.55%
cases:48.21%
controls:44.52%
125
1390
376
3620
123
1219
378
3791
78
250
423
4760
35
14
466
4996
83
277
417
4727
162
1256
329
3659
215
1986
231
2475
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
-1.4e-01
1.2e-02
1.3e+00
3.3e+00
1.2e+00
3.6e-01
1.5e-01
cases:24.95%
controls:27.74%
cases:24.55%
controls:24.33%
cases:15.57%
controls:4.99%
cases:6.99%
controls:0.28%
cases:16.60%
controls:5.54%
cases:32.99%
controls:25.55%
cases:48.21%
controls:44.47%
125
1390
376
3620
123
1219
378
3791
78
250
423
4760
35
14
466
4996
83
277
417
4727
162
1256
329
3659
215
1984
231
2477
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
-1.3e-01
1.2e-02
1.3e+00
3.3e+00
1.2e+00
3.6e-01
1.5e-01
cases:25.15%
controls:27.74%
cases:24.55%
controls:24.33%
cases:15.57%
controls:4.99%
cases:6.99%
controls:0.28%
cases:16.60%
controls:5.54%
cases:32.99%
controls:25.57%
cases:48.21%
controls:44.50%
126
1390
375
3620
123
1219
378
3791
78
250
423
4760
35
14
466
4996
83
277
417
4727
162
1257
329
3658
215
1985
231
2476
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
-1.3e-01
1.1e-02
1.2e+00
3.3e+00
1.2e+00
3.6e-01
1.5e-01
cases:25.15%
controls:27.74%
cases:24.55%
controls:24.35%
cases:15.57%
controls:5.03%
cases:6.99%
controls:0.28%
cases:16.60%
controls:5.52%
cases:32.99%
controls:25.60%
cases:48.21%
controls:44.54%
126
1390
375
3620
123
1220
378
3790
78
252
423
4758
35
14
466
4996
83
276
417
4728
162
1258
329
3657
215
1987
231
2474
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
-1.3e-01
1.1e-02
1.3e+00
3.3e+00
1.2e+00
3.6e-01
1.5e-01
cases:25.15%
controls:27.74%
cases:24.55%
controls:24.35%
cases:15.57%
controls:5.01%
cases:6.99%
controls:0.28%
cases:16.60%
controls:5.54%
cases:32.99%
controls:25.62%
cases:48.21%
controls:44.50%
126
1390
375
3620
123
1220
378
3790
78
251
423
4759
35
14
466
4996
83
277
417
4727
162
1259
329
3656
215
1985
231
2476
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
-1.2e-01
2.4e-02
1.3e+00
3.3e+00
1.2e+00
3.6e-01
1.5e-01
cases:25.35%
controls:27.76%
cases:24.75%
controls:24.31%
cases:15.57%
controls:5.01%
cases:6.99%
controls:0.28%
cases:16.60%
controls:5.56%
cases:32.99%
controls:25.64%
cases:48.21%
controls:44.52%
127
1391
374
3619
124
1218
377
3792
78
251
423
4759
35
14
466
4996
83
278
417
4726
162
1260
329
3655
215
1986
231
2475
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
-1.3e-01
-3.3e-02
1.3e+00
3.4e+00
1.3e+00
2.2e-02
1.6e-01
cases:21.36%
controls:23.55%
cases:16.57%
controls:17.03%
cases:9.38%
controls:2.85%
cases:4.79%
controls:0.16%
cases:10.00%
controls:3.00%
cases:18.33%
controls:18.01%
cases:38.79%
controls:35.04%
107
1180
394
3830
83
853
418
4157
47
143
454
4867
24
8
477
5002
50
150
450
4854
90
885
401
4030
173
1563
273
2898
Infiltrating duct carcinoma, NOS, of breast, NOS
8500/3-C50.9 [44505315]
8500/3-C50.9 [44505315]
1.1e+00
4.5e+00
—
—
—
—
1.4e+00
cases:2.00%
controls:0.66%
cases:10.18%
controls:0.12%
—
—
—
—
—
—
—
—
cases:2.24%
controls:0.56%
10
33
491
4977
51
6
450
5004
—
—
—
—
10
25
436
4436
Sentinel node biopsy
PJA12 [2001309627]
PJA12 [2001309627]
7.7e-01
2.5e+00
1.0e+50
1.0e+50
—
3.4e+00
1.0e+00
cases:2.59%
controls:1.22%
cases:3.59%
controls:0.30%
cases:4.79%
controls:0.00%
cases:7.78%
controls:0.00%
—
—
cases:5.70%
controls:0.20%
cases:2.47%
controls:0.92%
13
61
488
4949
18
15
483
4995
24
0
477
5010
39
0
462
5010
—
28
10
463
4905
11
41
435
4420
dexamethasone; oral, parenteral
H02AB02 [21602730]
H02AB02 [21602730]
-1.1e-01
5.8e-01
—
—
2.7e+00
2.3e+00
8.4e-01
cases:2.40%
controls:2.67%
cases:1.80%
controls:1.02%
—
—
—
—
cases:1.80%
controls:0.12%
cases:7.33%
controls:0.79%
cases:7.40%
controls:3.34%
12
134
489
4876
9
51
492
4959
—
—
9
6
491
4998
36
39
455
4876
33
149
413
4312
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
-1.7e-01
1.5e-02
1.2e+00
3.1e+00
1.1e+00
3.8e-01
2.3e-01
cases:22.36%
controls:25.39%
cases:22.36%
controls:22.10%
cases:13.77%
controls:4.51%
cases:5.99%
controls:0.28%
cases:13.00%
controls:4.90%
cases:30.35%
controls:22.87%
cases:47.53%
controls:41.96%
112
1272
389
3738
112
1107
389
3903
69
226
432
4784
30
14
471
4996
65
245
435
4759
149
1124
342
3791
212
1872
234
2589
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
2.0e-01
6.0e-01
—
1.0e+50
3.5e+00
1.2e+00
9.8e-01
cases:6.39%
controls:5.29%
cases:2.79%
controls:1.56%
—
—
cases:2.00%
controls:0.00%
cases:4.60%
controls:0.14%
cases:3.26%
controls:1.00%
cases:8.74%
controls:3.47%
32
265
469
4745
14
78
487
4932
—
10
0
491
5010
23
7
477
4997
16
49
475
4866
39
155
407
4306
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
-1.1e-01
6.7e-02
1.3e+00
3.1e+00
1.4e+00
2.5e-01
7.6e-02
cases:28.34%
controls:30.66%
cases:31.14%
controls:29.72%
cases:27.94%
controls:9.44%
cases:10.98%
controls:0.58%
cases:28.20%
controls:9.19%
cases:36.86%
controls:31.33%
cases:50.00%
controls:48.11%
142
1536
359
3474
156
1489
345
3521
140
473
361
4537
55
29
446
4981
141
460
359
4544
181
1540
310
3375
223
2146
223
2315
Malignant tumor of the upper outer quadrant of the mammary gland, other or undeterminated histology
C50.49 [2000501004]
C50.49 [2000501004]
—
—
—
1.0e+50
—
3.4e+00
2.2e+00
—
—
—
—
—
—
cases:1.60%
controls:0.00%
—
—
cases:3.05%
controls:0.10%
cases:3.14%
controls:0.36%
—
—
—
8
0
493
5010
—
15
5
476
4910
14
16
432
4445
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
-1.7e-01
-7.3e-02
1.3e+00
3.2e+00
1.1e+00
1.2e-01
1.3e-01
cases:20.96%
controls:23.89%
cases:18.76%
controls:19.90%
cases:11.58%
controls:3.57%
cases:5.79%
controls:0.26%
cases:10.60%
controls:3.78%
cases:22.61%
controls:20.51%
cases:42.83%
controls:39.72%
105
1197
396
3813
94
997
407
4013
58
179
443
4831
29
13
472
4997
53
189
447
4815
111
1008
380
3907
191
1772
255
2689
tamoxifen; oral
L02BA01 [21603831]
L02BA01 [21603831]
0.0e+00
—
—
—
—
2.7e+00
2.8e+00
cases:1.00%
controls:1.00%
—
—
—
—
—
—
—
—
cases:6.52%
controls:0.45%
cases:11.66%
controls:0.81%
5
50
496
4960
—
—
—
—
32
22
459
4893
52
36
394
4425
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
-1.6e-01
-7.5e-02
1.3e+00
3.2e+00
1.0e+00
1.4e-01
1.3e-01
cases:20.96%
controls:23.77%
cases:18.56%
controls:19.72%
cases:11.78%
controls:3.47%
cases:5.79%
controls:0.26%
cases:9.80%
controls:3.68%
cases:22.61%
controls:20.33%
cases:42.60%
controls:39.52%
105
1191
396
3819
93
988
408
4022
59
174
442
4836
29
13
472
4997
49
184
451
4820
111
999
380
3916
190
1763
256
2698
Malignant neoplasm: Upper-outer quadrant of breast
C50.4 [45561816]
C50.4 [45561816]
—
—
—
—
1.0e+50
3.6e+00
1.9e+00
—
—
—
—
—
—
—
—
cases:1.00%
controls:0.00%
cases:4.28%
controls:0.12%
cases:3.81%
controls:0.58%
—
—
—
—
5
0
495
5004
21
6
470
4909
17
26
429
4435
Breast Pathology biopsy report
66110-8 [40768793]
66110-8 [40768793]
1.2e+00
3.5e+00
1.0e+50
—
1.0e+50
—
2.0e+00
cases:1.60%
controls:0.50%
cases:5.39%
controls:0.18%
cases:6.59%
controls:0.00%
—
—
cases:1.20%
controls:0.00%
—
—
cases:3.59%
controls:0.52%
8
25
493
4985
27
9
474
5001
33
0
468
5010
—
6
0
494
5004
—
16
23
430
4438
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
-5.2e-01
-3.0e-01
1.2e+00
—
2.0e+00
1.4e+00
7.0e-01
cases:4.39%
controls:7.19%
cases:3.39%
controls:4.53%
cases:2.99%
controls:0.92%
—
—
cases:5.60%
controls:0.80%
cases:15.89%
controls:4.54%
cases:21.75%
controls:12.17%
22
360
479
4650
17
227
484
4783
15
46
486
4964
—
28
40
472
4964
78
223
413
4692
97
543
349
3918
Total mastectomy
HAC20 [2001303934]
HAC20 [2001303934]
8.6e-01
3.4e+00
—
1.0e+50
—
—
1.9e+00
cases:1.40%
controls:0.60%
cases:2.79%
controls:0.10%
—
—
cases:6.79%
controls:0.00%
—
—
—
—
cases:3.14%
controls:0.49%
7
30
494
4980
14
5
487
5005
—
34
0
467
5010
—
—
14
22
432
4439
Breast cancer
115 [2001600115]
115 [2001600115]
-1.1e-01
1.4e+00
—
—
—
3.9e+00
1.3e+00
cases:1.40%
controls:1.56%
cases:1.40%
controls:0.36%
—
—
—
—
—
—
cases:12.63%
controls:0.31%
cases:5.16%
controls:1.41%
7
78
494
4932
7
18
494
4992
—
—
—
62
15
429
4900
23
63
423
4398
Laceration/cut
S18 [2002000983]
S18 [2002000983]
-2.9e-01
3.1e-01
1.7e+00
—
2.4e+00
1.1e+00
3.3e-01
cases:4.99%
controls:6.59%
cases:2.79%
controls:2.06%
cases:1.80%
controls:0.34%
—
—
cases:2.60%
controls:0.24%
cases:5.50%
controls:1.93%
cases:11.66%
controls:8.65%
25
330
476
4680
14
103
487
4907
9
17
492
4993
—
13
12
487
4992
27
95
464
4820
52
386
394
4075
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
3.0e-03
-3.5e-01
1.7e+00
—
2.3e+00
1.1e+00
3.7e-01
cases:7.19%
controls:7.17%
cases:1.60%
controls:2.26%
cases:1.80%
controls:0.32%
—
—
cases:2.60%
controls:0.28%
cases:5.70%
controls:2.03%
cases:8.74%
controls:6.23%
36
359
465
4651
8
113
493
4897
9
16
492
4994
—
13
14
487
4990
28
100
463
4815
39
278
407
4183
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
-4.5e-01
-2.7e-01
—
—
2.8e+00
2.3e+00
4.1e-01
cases:2.40%
controls:3.71%
cases:1.20%
controls:1.56%
—
—
—
—
cases:2.20%
controls:0.14%
cases:9.78%
controls:1.12%
cases:6.73%
controls:4.55%
12
186
489
4824
6
78
495
4932
—
—
11
7
489
4997
48
55
443
4860
30
203
416
4258
granisetron; oral, parenteral, transdermal
A04AA02 [21600494]
A04AA02 [21600494]
—
—
—
—
—
3.5e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:4.68%
controls:0.14%
cases:2.24%
controls:0.52%
—
—
—
—
—
23
7
468
4908
10
23
436
4438
Radiotherapy after partial ablation of mammary gland
HA003 [2001303965]
HA003 [2001303965]
—
—
—
—
1.0e+50
5.0e+00
1.2e+00
—
—
—
—
—
—
—
—
cases:2.80%
controls:0.00%
cases:21.38%
controls:0.18%
cases:1.57%
controls:0.47%
—
—
—
—
14
0
486
5004
105
9
386
4906
7
21
439
4440
Overall malignant tumor of the mammary gland, ductal tumor
C50.81 [2000501014]
C50.81 [2000501014]
-1.0e+50
—
—
—
—
2.8e+00
2.1e+00
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:3.05%
controls:0.18%
cases:4.04%
controls:0.49%
0
12
501
4998
—
—
—
—
15
9
476
4906
18
22
428
4439
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
-7.0e-02
3.1e-02
5.4e-01
3.1e+00
9.0e-01
3.2e-01
1.4e-01
cases:50.30%
controls:52.04%
cases:46.71%
controls:45.95%
cases:27.35%
controls:17.98%
cases:21.36%
controls:1.24%
cases:35.40%
controls:18.25%
cases:56.21%
controls:48.14%
cases:69.96%
controls:66.87%
252
2607
249
2403
234
2302
267
2708
137
901
364
4109
107
62
394
4948
177
913
323
4091
276
2366
215
2549
312
2983
134
1478
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
-6.4e-03
-3.3e-02
2.0e+00
—
2.1e+00
4.8e-01
6.5e-01
cases:3.19%
controls:3.21%
cases:1.80%
controls:1.86%
cases:1.80%
controls:0.24%
—
—
cases:1.60%
controls:0.20%
cases:2.85%
controls:1.79%
cases:8.74%
controls:4.75%
16
161
485
4849
9
93
492
4917
9
12
492
4998
—
8
10
492
4994
14
88
477
4827
39
212
407
4249
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
3.6e-02
1.6e-01
1.8e+00
—
2.9e+00
9.7e-01
7.2e-01
cases:4.79%
controls:4.63%
cases:1.80%
controls:1.54%
cases:1.00%
controls:0.16%
—
—
cases:3.20%
controls:0.18%
cases:3.46%
controls:1.34%
cases:9.19%
controls:4.69%
24
232
477
4778
9
77
492
4933
5
8
496
5002
—
16
9
484
4995
17
66
474
4849
41
209
405
4252
Simple adjuvant hormone therapy of malignancy
WB203 [2001310635]
WB203 [2001310635]
-1.0e+50
-1.0e+50
—
—
—
2.2e+00
2.4e+00
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:1.63%
controls:0.18%
cases:3.59%
controls:0.34%
0
23
501
4987
0
10
501
5000
—
—
—
8
9
483
4906
16
15
430
4446
Radiotherapy with large shaped fields - isocentric therapy
ZX012 [2001311468]
ZX012 [2001311468]
—
—
—
—
—
4.6e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:12.02%
controls:0.14%
cases:1.35%
controls:0.38%
—
—
—
—
—
59
7
432
4908
6
17
440
4444
Malignant tumor of the lower inner quadrant of the mammary gland, ductal tumor
C50.31 [2000500998]
C50.31 [2000500998]
—
—
—
—
1.0e+50
2.7e+00
1.8e+00
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.00%
cases:2.04%
controls:0.14%
cases:2.02%
controls:0.34%
—
—
—
—
6
0
494
5004
10
7
481
4908
9
15
437
4446
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
-4.4e-02
4.3e-01
1.0e+00
—
1.8e+00
1.5e+00
1.1e+00
cases:4.19%
controls:4.37%
cases:3.39%
controls:2.24%
cases:1.00%
controls:0.36%
—
—
cases:3.20%
controls:0.52%
cases:10.79%
controls:2.60%
cases:15.47%
controls:5.92%
21
219
480
4791
17
112
484
4898
5
18
496
4992
—
16
26
484
4978
53
128
438
4787
69
264
377
4197
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
2.4e-02
3.1e-01
1.2e+00
—
2.3e+00
9.1e-01
9.3e-02
cases:25.75%
controls:25.29%
cases:11.18%
controls:8.46%
cases:2.79%
controls:0.84%
—
—
cases:8.00%
controls:0.88%
cases:19.14%
controls:8.69%
cases:28.25%
controls:26.41%
129
1267
372
3743
56
424
445
4586
14
42
487
4968
—
40
44
460
4960
94
427
397
4488
126
1178
320
3283
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
Z03.9 [45552062]
6.0e-01
—
—
1.0e+50
3.1e+00
1.3e+00
6.6e-01
cases:4.19%
controls:2.34%
—
—
—
—
cases:1.00%
controls:0.00%
cases:2.60%
controls:0.12%
cases:2.85%
controls:0.79%
cases:4.93%
controls:2.62%
21
117
480
4893
—
—
5
0
496
5010
13
6
487
4998
14
39
477
4876
22
117
424
4344
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
7.6e-02
3.1e-01
1.3e+00
—
2.4e+00
5.5e-01
3.0e-01
cases:15.77%
controls:14.79%
cases:7.39%
controls:5.51%
cases:2.20%
controls:0.60%
—
—
cases:8.40%
controls:0.82%
cases:10.59%
controls:6.37%
cases:22.87%
controls:18.05%
79
741
422
4269
37
276
464
4734
11
30
490
4980
—
42
41
458
4963
52
313
439
4602
102
805
344
3656
Reconstruction of breast using graft or flap
HAE10 [2001303956]
HAE10 [2001303956]
—
—
—
1.0e+50
1.0e+50
—
4.1e+00
—
—
—
—
—
—
cases:1.40%
controls:0.00%
cases:2.00%
controls:0.00%
—
—
cases:7.40%
controls:0.13%
—
—
—
7
0
494
5010
10
0
490
5004
—
33
6
413
4455
Internal Medicine
11 [38004456]
11 [38004456]
-1.7e-02
1.1e-01
7.2e-01
3.3e+00
8.9e-01
7.5e-01
2.0e-01
cases:18.76%
controls:19.02%
cases:7.98%
controls:7.21%
cases:2.00%
controls:0.98%
cases:2.59%
controls:0.10%
cases:2.40%
controls:1.00%
cases:12.63%
controls:6.39%
cases:22.42%
controls:19.14%
94
953
407
4057
40
361
461
4649
10
49
491
4961
13
5
488
5005
12
50
488
4954
62
314
429
4601
100
854
346
3607
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
2.8e-02
1.9e-01
1.0e+00
—
2.1e+00
5.9e-01
3.4e-01
cases:33.33%
controls:32.71%
cases:17.56%
controls:15.01%
cases:5.79%
controls:2.22%
—
—
cases:16.20%
controls:2.40%
cases:23.83%
controls:14.77%
cases:40.36%
controls:32.41%
167
1639
334
3371
88
752
413
4258
29
111
472
4899
—
81
120
419
4884
117
726
374
4189
180
1446
266
3015
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
2.8e-02
1.9e-01
1.0e+00
—
2.1e+00
5.9e-01
3.4e-01
cases:33.33%
controls:32.71%
cases:17.56%
controls:15.01%
cases:5.79%
controls:2.22%
—
—
cases:16.20%
controls:2.40%
cases:23.83%
controls:14.77%
cases:40.36%
controls:32.41%
167
1639
334
3371
88
752
413
4258
29
111
472
4899
—
81
120
419
4884
117
726
374
4189
180
1446
266
3015
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
-2.7e-01
-8.0e-02
9.4e-01
—
1.3e+00
1.0e+00
6.8e-01
cases:10.78%
controls:13.65%
cases:8.78%
controls:9.44%
cases:4.39%
controls:1.76%
—
—
cases:6.80%
controls:1.88%
cases:22.81%
controls:9.60%
cases:36.10%
controls:22.33%
54
684
447
4326
44
473
457
4537
22
88
479
4922
—
34
94
466
4910
112
472
379
4443
161
996
285
3465
letrozole; oral
L02BG04 [21603842]
L02BG04 [21603842]
—
—
—
—
1.6e+00
2.1e+00
1.9e+00
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.24%
cases:8.55%
controls:1.18%
cases:9.19%
controls:1.55%
—
—
—
—
6
12
494
4992
42
58
449
4857
41
69
405
4392
Supraglottic ventilation device
WX702 [2001310818]
WX702 [2001310818]
—
2.5e+00
1.0e+50
1.0e+50
—
—
1.4e+00
—
—
cases:1.40%
controls:0.12%
cases:1.80%
controls:0.00%
cases:1.20%
controls:0.00%
—
—
—
—
cases:2.47%
controls:0.61%
—
7
6
494
5004
9
0
492
5010
6
0
495
5010
—
—
11
27
435
4434
Malignant tumor of the lower outer quadrant of the mammary gland, ductal tumor
C50.51 [2000501006]
C50.51 [2000501006]
—
—
—
—
—
2.0e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:1.83%
controls:0.24%
cases:2.24%
controls:0.36%
—
—
—
—
—
9
12
482
4903
10
16
436
4445
Pathology report gross observation
24419-4 [3002256]
24419-4 [3002256]
-2.2e-02
3.9e-01
—
—
—
2.3e+00
1.6e+00
cases:1.80%
controls:1.84%
cases:1.00%
controls:0.68%
—
—
—
—
—
—
cases:4.07%
controls:0.43%
cases:6.95%
controls:1.55%
9
92
492
4918
5
34
496
4976
—
—
—
20
21
471
4894
31
69
415
4392
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
-1.3e-01
4.6e-02
2.3e+00
—
1.5e+00
1.5e-01
3.3e-01
cases:11.58%
controls:12.93%
cases:7.58%
controls:7.27%
cases:8.78%
controls:0.96%
—
—
cases:4.60%
controls:1.04%
cases:8.55%
controls:7.47%
cases:26.68%
controls:20.76%
58
648
443
4362
38
364
463
4646
44
48
457
4962
—
23
52
477
4952
42
367
449
4548
119
926
327
3535
Multiple adjuvant cytostatic therapy
WB113 [2001310629]
WB113 [2001310629]
—
—
—
—
—
3.7e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.07%
controls:0.10%
—
—
—
—
—
—
—
20
5
471
4910
—
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
5.4e-02
-1.5e-01
9.7e-01
—
1.4e+00
1.4e+00
9.3e-01
cases:5.19%
controls:4.93%
cases:2.20%
controls:2.53%
cases:1.00%
controls:0.38%
—
—
cases:2.20%
controls:0.54%
cases:10.79%
controls:3.03%
cases:17.04%
controls:7.46%
26
247
475
4763
11
127
490
4883
5
19
496
4991
—
11
27
489
4977
53
149
438
4766
76
333
370
4128
Malignant tumor of the upper inner quadrant of the mammary gland,ductal tumor
C50.21 [2000500994]
C50.21 [2000500994]
—
—
—
1.0e+50
—
2.0e+00
1.7e+00
—
—
—
—
—
—
cases:1.00%
controls:0.00%
—
—
cases:2.04%
controls:0.28%
cases:2.91%
controls:0.54%
—
—
—
5
0
496
5010
—
10
14
481
4901
13
24
433
4437
Other reconstruction of breast
HAE99 [2001303958]
HAE99 [2001303958]
—
—
—
—
—
—
3.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:0.11%
—
—
—
—
—
—
19
5
427
4456
Doppler ultrasound examination of heart
FM1DE [2001303299]
FM1DE [2001303299]
—
—
—
—
—
2.0e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:1.63%
controls:0.22%
cases:4.26%
controls:1.03%
—
—
—
—
—
8
11
483
4904
19
46
427
4415
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
1.2e-02
-5.3e-01
1.2e+00
—
2.6e+00
8.7e-01
4.8e-01
cases:6.99%
controls:6.91%
cases:1.60%
controls:2.67%
cases:1.40%
controls:0.42%
—
—
cases:4.80%
controls:0.38%
cases:5.70%
controls:2.48%
cases:11.21%
controls:7.26%
35
346
466
4664
8
134
493
4876
7
21
494
4989
—
24
19
476
4985
28
122
463
4793
50
324
396
4137
Malignant tumor in another specified localization in ductal mammary gland
C50.91 [2000501018]
C50.91 [2000501018]
—
—
—
—
—
—
3.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.36%
controls:0.11%
—
—
—
—
—
—
15
5
431
4456
ABO and Rh group [Type] in Blood
882-1 [3003694]
882-1 [3003694]
4.4e-02
7.4e-01
3.4e+00
1.0e+50
—
—
-9.3e-02
cases:2.40%
controls:2.30%
cases:2.59%
controls:1.26%
cases:2.99%
controls:0.10%
cases:3.39%
controls:0.00%
—
—
—
—
cases:3.59%
controls:3.92%
12
115
489
4895
13
63
488
4947
15
5
486
5005
17
0
484
5010
—
—
16
175
430
4286
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
4.7e-01
6.8e-01
—
—
—
2.0e+00
1.4e+00
cases:5.19%
controls:3.31%
cases:1.60%
controls:0.82%
—
—
—
—
—
—
cases:4.28%
controls:0.63%
cases:7.85%
controls:2.00%
26
166
475
4844
8
41
493
4969
—
—
—
21
31
470
4884
35
89
411
4372
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
-5.1e-01
2.2e-02
1.7e+00
1.0e+50
1.7e+00
2.9e-01
8.6e-02
cases:3.79%
controls:6.17%
cases:3.79%
controls:3.71%
cases:2.79%
controls:0.54%
cases:1.40%
controls:0.00%
cases:2.60%
controls:0.48%
cases:5.09%
controls:3.85%
cases:10.99%
controls:10.18%
19
309
482
4701
19
186
482
4824
14
27
487
4983
7
0
494
5010
13
24
487
4980
25
189
466
4726
49
454
397
4007
Personal history of malignant neoplasm of breast
Z85.3 [45547353]
Z85.3 [45547353]
-1.0e+50
—
—
—
—
—
3.2e+00
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
cases:7.62%
controls:0.34%
0
5
501
5005
—
—
—
—
—
34
15
412
4446
Intraductal carcinoma, noninfiltrating, NOS, of breast, NOS
8500/2-C50.9 [44505314]
8500/2-C50.9 [44505314]
3.1e+00
—
1.0e+50
—
1.0e+50
—
—
cases:2.59%
controls:0.12%
—
—
cases:14.57%
controls:0.00%
—
—
cases:3.20%
controls:0.00%
—
—
—
—
13
6
488
5004
—
73
0
428
5010
—
16
0
484
5004
—
—
Reduction mammoplasty with transposition of areola
HAD30 [2001303943]
HAD30 [2001303943]
—
2.3e+00
—
1.0e+50
—
—
3.1e+00
—
—
cases:1.00%
controls:0.10%
—
—
cases:1.00%
controls:0.00%
—
—
—
—
cases:4.71%
controls:0.22%
—
5
5
496
5005
—
5
0
496
5010
—
—
21
10
425
4451
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
-4.7e-03
1.1e-02
8.8e-01
—
1.8e+00
3.8e-01
2.6e-01
cases:30.54%
controls:30.64%
cases:17.37%
controls:17.21%
cases:7.19%
controls:3.11%
—
—
cases:17.00%
controls:3.20%
cases:24.24%
controls:17.99%
cases:45.07%
controls:38.76%
153
1535
348
3475
87
862
414
4148
36
156
465
4854
—
85
160
415
4844
119
884
372
4031
201
1729
245
2732
More than five and less than seven hours
ZXE30 [2001311411]
ZXE30 [2001311411]
7.0e-01
—
—
—
—
—
3.0e+00
cases:1.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:2.24%
controls:0.11%
5
25
496
4985
—
—
—
—
—
10
5
436
4456
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
-2.7e-01
8.6e-02
3.8e-01
—
1.3e+00
1.1e+00
5.8e-01
cases:7.39%
controls:9.42%
cases:6.19%
controls:5.71%
cases:1.60%
controls:1.10%
—
—
cases:4.60%
controls:1.32%
cases:17.11%
controls:6.29%
cases:21.75%
controls:13.49%
37
472
464
4538
31
286
470
4724
8
55
493
4955
—
23
66
477
4938
84
309
407
4606
97
602
349
3859
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-1.3e+00
-1.2e+00
8.0e-01
—
—
2.6e+00
2.9e+00
cases:9.98%
controls:29.44%
cases:2.99%
controls:9.62%
cases:1.80%
controls:0.82%
—
—
—
—
cases:4.68%
controls:0.35%
cases:13.00%
controls:0.83%
50
1475
451
3535
15
482
486
4528
9
41
492
4969
—
—
23
17
468
4898
58
37
388
4424
Left side
ZXA05 [2001311347]
ZXA05 [2001311347]
2.1e-01
1.4e+00
—
—
—
1.5e+00
4.6e-01
cases:4.39%
controls:3.57%
cases:2.79%
controls:0.70%
—
—
—
—
—
—
cases:3.26%
controls:0.73%
cases:4.93%
controls:3.18%
22
179
479
4831
14
35
487
4975
—
—
—
16
36
475
4879
22
142
424
4319
Extra corporeal mammography of operated mammary gland
HA6AA [2001303914]
HA6AA [2001303914]
—
—
1.0e+50
1.0e+50
—
2.9e+00
8.7e-01
—
—
—
—
cases:3.39%
controls:0.00%
cases:1.60%
controls:0.00%
—
—
cases:2.85%
controls:0.16%
cases:1.12%
controls:0.47%
—
—
17
0
484
5010
8
0
493
5010
—
14
8
477
4907
5
21
441
4440
Malignant tumor in other or unspecified location in mammary gland without histology
C50.90 [2000501017]
C50.90 [2000501017]
1.2e+00
—
1.0e+50
—
—
—
2.9e+00
cases:1.00%
controls:0.30%
—
—
cases:1.00%
controls:0.00%
—
—
—
—
—
—
cases:3.81%
controls:0.22%
5
15
496
4995
—
5
0
496
5010
—
—
—
17
10
429
4451
Block dissection of axillary lymph nodes
PJD52 [2001309638]
PJD52 [2001309638]
-1.0e+50
2.8e+00
—
1.0e+50
—
—
8.7e-01
cases:0.00%
controls:0.56%
cases:1.60%
controls:0.10%
—
—
cases:2.40%
controls:0.00%
—
—
—
—
cases:1.12%
controls:0.47%
0
28
501
4982
8
5
493
5005
—
12
0
489
5010
—
—
5
21
441
4440
Other partial excision of mammary gland
HAB99 [2001303930]
HAB99 [2001303930]
—
2.7e+00
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
cases:1.80%
controls:0.12%
cases:2.00%
controls:0.00%
cases:1.00%
controls:0.00%
cases:3.20%
controls:0.00%
—
—
—
—
—
9
6
492
5004
10
0
491
5010
5
0
496
5010
16
0
484
5004
—
—
Malignant tumor of the central part of the mammary gland,ductal tumor
C50.11 [2000500990]
C50.11 [2000500990]
—
—
—
—
1.0e+50
—
2.7e+00
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.00%
—
—
cases:4.26%
controls:0.29%
—
—
—
—
6
0
494
5004
—
19
13
427
4448
Simple adjuvant cytostatic therapy
WB103 [2001310627]
WB103 [2001310627]
-1.0e+50
—
—
—
—
2.7e+00
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:2.04%
controls:0.14%
—
—
0
23
501
4987
—
—
—
—
10
7
481
4908
—
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
—
—
2.7e+00
1.0e+50
—
8.3e-01
—
—
—
—
—
cases:1.40%
controls:0.10%
cases:1.20%
controls:0.00%
—
—
cases:1.02%
controls:0.45%
—
—
—
—
7
5
494
5005
6
0
495
5010
—
5
22
486
4893
—
Emergency Room Visit
ER [9203]
ER [9203]
-6.8e-02
4.8e-01
8.0e-01
—
1.4e+00
7.7e-01
1.0e-02
cases:26.35%
controls:27.68%
cases:14.17%
controls:9.30%
cases:2.79%
controls:1.28%
—
—
cases:5.20%
controls:1.34%
cases:16.90%
controls:8.59%
cases:27.35%
controls:27.15%
132
1387
369
3623
71
466
430
4544
14
64
487
4946
—
26
67
474
4937
83
422
408
4493
122
1211
324
3250
Family history of malignant neoplasm of breast
Z80.3 [45556856]
Z80.3 [45556856]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.20%
—
—
—
—
—
—
12
9
434
4452
Follow-up examination after surgery for malignant neoplasm
Z08.0 [45556811]
Z08.0 [45556811]
—
-1.0e+50
—
—
—
2.6e+00
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:1.63%
controls:0.12%
—
—
—
0
7
501
5003
—
—
—
8
6
483
4909
—
General anaesthesia
WX402 [2001310806]
WX402 [2001310806]
4.3e-01
4.9e-01
—
—
—
1.7e+00
7.8e-01
cases:2.20%
controls:1.44%
cases:1.40%
controls:0.86%
—
—
—
—
—
—
cases:3.67%
controls:0.67%
cases:5.61%
controls:2.65%
11
72
490
4938
7
43
494
4967
—
—
—
18
33
473
4882
25
118
421
4343
Malignant neoplasm: Breast, unspecified
C50.9 [45547505]
C50.9 [45547505]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.16%
—
—
—
—
—
—
8
7
438
4454
Malignant tumor of the upper outer quadrant of the mammary gland, no histological veryfication
C50.40 [2000501001]
C50.40 [2000501001]
—
—
1.0e+50
—
—
2.5e+00
1.7e+00
—
—
—
—
cases:1.60%
controls:0.00%
—
—
—
—
cases:1.63%
controls:0.14%
cases:1.57%
controls:0.29%
—
—
8
0
493
5010
—
—
8
7
483
4908
7
13
439
4448
Genetic counselling
Z31.5 [45590715]
Z31.5 [45590715]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.93%
controls:0.45%
—
—
—
—
—
—
22
20
424
4441
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
—
—
—
—
—
2.3e+00
5.2e-01
—
—
—
—
—
—
—
—
—
—
cases:1.83%
controls:0.18%
cases:1.79%
controls:1.08%
—
—
—
—
—
9
9
482
4906
8
48
438
4413
Other specified counselling
Z71.8 [45581061]
Z71.8 [45581061]
-3.3e-01
4.7e-01
2.3e+00
—
—
4.4e-01
4.5e-01
cases:2.40%
controls:3.29%
cases:2.20%
controls:1.38%
cases:1.20%
controls:0.12%
—
—
—
—
cases:2.65%
controls:1.73%
cases:9.19%
controls:6.07%
12
165
489
4845
11
69
490
4941
6
6
495
5004
—
—
13
85
478
4830
41
271
405
4190
venlafaxine; oral
N06AX16 [21604745]
N06AX16 [21604745]
-5.4e-01
-4.6e-01
—
—
—
1.0e+00
1.3e+00
cases:1.40%
controls:2.38%
cases:1.00%
controls:1.58%
—
—
—
—
—
—
cases:3.67%
controls:1.38%
cases:8.30%
controls:2.40%
7
119
494
4891
5
79
496
4931
—
—
—
18
68
473
4847
37
107
409
4354
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
OMOP4822000 [32411]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.61%
controls:0.61%
—
—
—
—
—
—
25
27
421
4434
Excision of other lesion extending through all layers of skin of trunk
QBE10 [2001309853]
QBE10 [2001309853]
—
-1.0e+50
—
—
—
—
2.2e+00
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:3.59%
controls:0.40%
—
0
12
501
4998
—
—
—
—
16
18
430
4443
Cell count panel - Synovial fluid
34559-5 [3044941]
34559-5 [3044941]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.35%
controls:0.16%
—
—
—
—
—
—
6
7
440
4454
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
T81.0 [45599741]
T81.0 [45599741]
—
—
—
—
1.0e+50
2.2e+00
1.2e+00
—
—
—
—
—
—
—
—
cases:1.60%
controls:0.00%
cases:1.22%
controls:0.14%
cases:1.57%
controls:0.47%
—
—
—
—
8
0
492
5004
6
7
485
4908
7
21
439
4440
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
-4.2e-01
—
—
—
2.2e+00
9.6e-01
4.0e-01
cases:2.00%
controls:2.99%
—
—
—
—
—
—
cases:1.20%
controls:0.14%
cases:1.63%
controls:0.63%
cases:3.36%
controls:2.29%
10
150
491
4860
—
—
—
6
7
494
4997
8
31
483
4884
15
102
431
4359
Hypertrophy of breast
N62 [45577538]
N62 [45577538]
—
—
—
1.0e+50
—
—
2.1e+00
—
—
—
—
—
—
cases:1.40%
controls:0.00%
—
—
—
—
cases:2.24%
controls:0.27%
—
—
—
7
0
494
5010
—
—
10
12
436
4449
exemestane; oral
L02BG06 [21603844]
L02BG06 [21603844]
—
—
—
—
—
1.8e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:1.02%
controls:0.16%
cases:2.02%
controls:0.25%
—
—
—
—
—
5
8
486
4907
9
11
437
4450
EKG study
11524-6 [3013512]
11524-6 [3013512]
-2.5e-02
4.9e-02
—
1.0e+50
2.1e+00
-1.1e-01
-3.0e-01
cases:4.99%
controls:5.11%
cases:2.99%
controls:2.85%
—
—
cases:1.40%
controls:0.00%
cases:2.60%
controls:0.32%
cases:3.05%
controls:3.40%
cases:7.17%
controls:9.41%
25
256
476
4754
15
143
486
4867
—
7
0
494
5010
13
16
487
4988
15
167
476
4748
32
420
414
4041
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
3.2e-01
—
—
—
—
1.3e+00
2.1e+00
cases:1.40%
controls:1.02%
—
—
—
—
—
—
—
—
cases:1.02%
controls:0.28%
cases:4.48%
controls:0.58%
7
51
494
4959
—
—
—
—
5
14
486
4901
20
26
426
4435
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
T81.4 [45575538]
1.3e-01
—
—
—
—
2.1e+00
6.6e-01
cases:1.00%
controls:0.88%
—
—
—
—
—
—
—
—
cases:2.04%
controls:0.26%
cases:2.02%
controls:1.05%
5
44
496
4966
—
—
—
—
10
13
481
4902
9
47
437
4414
Malignant neoplasm breast female
X76 [2002001361]
X76 [2002001361]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.02%
controls:0.27%
—
—
—
—
—
—
9
12
437
4449
Hypothyroidism, unspecified
E03.9 [45537945]
E03.9 [45537945]
-7.6e-02
2.0e-01
1.7e+00
—
2.0e+00
4.9e-01
-1.1e-01
cases:2.59%
controls:2.79%
cases:1.60%
controls:1.32%
cases:1.20%
controls:0.22%
—
—
cases:1.20%
controls:0.16%
cases:2.24%
controls:1.38%
cases:3.14%
controls:3.47%
13
140
488
4870
8
66
493
4944
6
11
495
4999
—
6
8
494
4996
11
68
480
4847
14
155
432
4306
ipratropium bromide; nasal
R01AX03 [21603199]
R01AX03 [21603199]
—
—
—
—
—
-1.0e+50
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
cases:1.57%
controls:0.22%
—
—
—
—
—
0
5
491
4910
7
10
439
4451
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
—
—
—
—
—
2.0e+00
4.8e-01
—
—
—
—
—
—
—
—
—
—
cases:1.83%
controls:0.26%
cases:1.12%
controls:0.69%
—
—
—
—
—
9
13
482
4902
5
31
441
4430
Major dressing of wound of skin of trunk
QBB10 [2001309842]
QBB10 [2001309842]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.36%
—
—
—
—
—
—
11
16
435
4445
Teaching
WZC30 [2001310891]
WZC30 [2001310891]
—
—
—
—
—
1.9e+00
2.1e-01
—
—
—
—
—
—
—
—
—
—
cases:3.26%
controls:0.51%
cases:2.47%
controls:2.02%
—
—
—
—
—
16
25
475
4890
11
90
435
4371
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
29265-6 [3020059]
-4.3e-01
-3.3e-01
—
—
1.9e+00
6.4e-01
5.5e-01
cases:1.80%
controls:2.73%
cases:1.00%
controls:1.38%
—
—
—
—
cases:1.40%
controls:0.22%
cases:3.05%
controls:1.63%
cases:6.50%
controls:3.86%
9
137
492
4873
5
69
496
4941
—
—
7
11
493
4993
15
80
476
4835
29
172
417
4289
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
—
—
—
—
—
1.8e+00
2.3e-01
—
—
—
—
—
—
—
—
—
—
cases:1.63%
controls:0.26%
cases:1.35%
controls:1.08%
—
—
—
—
—
8
13
483
4902
6
48
440
4413
Pure hypercholesterolaemia
E78.01 [2000501514]
E78.01 [2000501514]
-2.0e-01
4.8e-01
—
1.0e+50
1.8e+00
8.9e-02
-2.2e-01
cases:2.00%
controls:2.44%
cases:1.80%
controls:1.12%
—
—
cases:1.00%
controls:0.00%
cases:1.40%
controls:0.24%
cases:1.22%
controls:1.12%
cases:4.04%
controls:4.98%
10
122
491
4888
9
56
492
4954
—
5
0
496
5010
7
12
493
4992
6
55
485
4860
18
222
428
4239
Rhinopharyngoscopy
UDH02 [2001301680]
UDH02 [2001301680]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.34%
—
—
—
—
—
—
8
15
438
4446
Endovenous obliteration of v.saphena magna
PHM76 [2001309538]
PHM76 [2001309538]
1.7e+00
-1.0e+50
—
—
—
—
—
cases:1.60%
controls:0.30%
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
8
15
493
4995
0
5
501
5005
—
—
—
—
—
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
A04AA01 [21600493]
—
—
-1.0e+50
—
—
1.7e+00
5.2e-01
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
cases:2.04%
controls:0.39%
cases:1.57%
controls:0.94%
—
—
0
5
501
5005
—
—
10
19
481
4896
7
42
439
4419
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
-1.5e-01
—
—
—
—
1.7e+00
3.1e-01
cases:1.40%
controls:1.62%
—
—
—
—
—
—
—
—
cases:2.85%
controls:0.55%
cases:2.69%
controls:2.00%
7
81
494
4929
—
—
—
—
14
27
477
4888
12
89
434
4372
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
2.4e-01
—
—
—
—
1.6e+00
7.0e-01
cases:2.20%
controls:1.74%
—
—
—
—
—
—
—
—
cases:1.63%
controls:0.33%
cases:3.81%
controls:1.93%
11
87
490
4923
—
—
—
—
8
16
483
4899
17
86
429
4375
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
1.1e-01
1.4e-01
4.1e-01
—
1.5e+00
5.1e-01
3.3e-01
cases:12.97%
controls:11.78%
cases:5.79%
controls:5.09%
cases:1.20%
controls:0.80%
—
—
cases:4.80%
controls:1.10%
cases:8.15%
controls:5.07%
cases:17.71%
controls:13.43%
65
590
436
4420
29
255
472
4755
6
40
495
4970
—
24
55
476
4949
40
249
451
4666
79
599
367
3862
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
6.3e-02
4.8e-01
1.5e+00
—
—
4.0e-01
4.2e-01
cases:8.18%
controls:7.72%
cases:4.19%
controls:2.63%
cases:1.80%
controls:0.42%
—
—
—
—
cases:4.48%
controls:3.05%
cases:13.00%
controls:8.92%
41
387
460
4623
21
132
480
4878
9
21
492
4989
—
—
22
150
469
4765
58
398
388
4063
Preventive immunization/medic
-44 [2002000115]
-44 [2002000115]
1.5e+00
—
—
—
—
—
1.4e+00
cases:2.20%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:2.24%
controls:0.58%
11
26
490
4984
—
—
—
—
—
10
26
436
4435
More than three and less than five hours
ZXE20 [2001311408]
ZXE20 [2001311408]
-1.4e-01
1.6e+00
—
—
—
1.7e+00
1.5e+00
cases:1.40%
controls:1.60%
cases:1.40%
controls:0.28%
—
—
—
—
—
—
cases:1.02%
controls:0.18%
cases:2.91%
controls:0.69%
7
80
494
4930
7
14
494
4996
—
—
—
5
9
486
4906
13
31
433
4430
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
-8.4e-02
4.9e-03
-7.1e-02
—
8.7e-01
5.3e-01
1.7e-01
cases:20.36%
controls:21.76%
cases:14.17%
controls:14.11%
cases:2.79%
controls:2.99%
—
—
cases:6.80%
controls:2.96%
cases:23.01%
controls:14.99%
cases:36.77%
controls:32.95%
102
1090
399
3920
71
707
430
4303
14
150
487
4860
—
34
148
466
4856
113
737
378
4178
164
1470
282
2991
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
M01AB05 [21603945]
2.7e-02
6.0e-02
—
—
1.3e+00
9.9e-03
4.2e-02
cases:16.17%
controls:15.81%
cases:6.19%
controls:5.85%
—
—
—
—
cases:2.20%
controls:0.60%
cases:4.89%
controls:4.84%
cases:15.47%
controls:14.93%
81
792
420
4218
31
293
470
4717
—
—
11
30
489
4974
24
238
467
4677
69
666
377
3795
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
-2.1e-01
9.3e-02
6.9e-01
—
1.2e+00
4.0e-01
2.8e-04
cases:12.18%
controls:14.65%
cases:7.78%
controls:7.15%
cases:2.40%
controls:1.22%
—
—
cases:3.40%
controls:1.04%
cases:10.59%
controls:7.39%
cases:21.08%
controls:21.07%
61
734
440
4276
39
358
462
4652
12
61
489
4949
—
17
52
483
4952
52
363
439
4552
94
940
352
3521
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
-1.9e-01
-9.7e-02
4.9e-01
—
7.5e-01
4.6e-01
1.6e-01
cases:20.36%
controls:23.55%
cases:17.96%
controls:19.44%
cases:5.19%
controls:3.23%
—
—
cases:8.00%
controls:3.96%
cases:28.11%
controls:19.86%
cases:43.72%
controls:39.88%
102
1180
399
3830
90
974
411
4036
26
162
475
4848
—
40
198
460
4806
138
976
353
3939
195
1779
251
2682
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
2039-6 [3003785]
-2.4e-01
3.6e-01
—
—
—
9.0e-01
1.2e+00
cases:1.20%
controls:1.52%
cases:1.20%
controls:0.84%
—
—
—
—
—
—
cases:1.83%
controls:0.75%
cases:5.16%
controls:1.64%
6
76
495
4934
6
42
495
4968
—
—
—
9
37
482
4878
23
73
423
4388
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
1.8e-01
5.8e-01
—
—
—
5.2e-01
1.1e+00
cases:1.20%
controls:1.00%
cases:1.00%
controls:0.56%
—
—
—
—
—
—
cases:1.02%
controls:0.61%
cases:4.93%
controls:1.64%
6
50
495
4960
5
28
496
4982
—
—
—
5
30
486
4885
22
73
424
4388
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
-2.3e-01
5.3e-02
9.0e-01
—
1.1e+00
4.4e-01
2.6e-01
cases:5.39%
controls:6.69%
cases:3.99%
controls:3.79%
cases:2.99%
controls:1.24%
—
—
cases:3.20%
controls:1.08%
cases:5.70%
controls:3.76%
cases:13.68%
controls:10.87%
27
335
474
4675
20
190
481
4820
15
62
486
4948
—
16
54
484
4950
28
185
463
4730
61
485
385
3976
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
-8.3e-02
—
—
—
—
—
1.0e+00
cases:1.40%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
cases:6.05%
controls:2.22%
7
76
494
4934
—
—
—
—
—
27
99
419
4362
calcium (different salts in combination); oral
A12AA20 [21600872]
A12AA20 [21600872]
7.8e-02
-9.7e-02
-2.5e-01
—
4.3e-01
5.0e-01
5.1e-01
cases:11.98%
controls:11.18%
cases:8.18%
controls:8.94%
cases:1.80%
controls:2.30%
—
—
cases:3.20%
controls:2.10%
cases:14.66%
controls:9.44%
cases:21.30%
controls:13.92%
60
560
441
4450
41
448
460
4562
9
115
492
4895
—
16
105
484
4899
72
464
419
4451
95
621
351
3840
Microorganisms panel - Urine sediment
58435-9 [40761536]
58435-9 [40761536]
—
—
—
—
-1.0e+50
—
1.0e+00
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
cases:4.26%
controls:1.61%
—
—
—
—
0
7
500
4997
—
19
72
427
4389
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
-5.5e-01
-2.3e-01
1.7e+00
—
1.5e+00
8.7e-01
1.5e-01
cases:4.19%
controls:7.05%
cases:2.20%
controls:2.75%
cases:1.00%
controls:0.18%
—
—
cases:1.20%
controls:0.26%
cases:5.70%
controls:2.48%
cases:8.74%
controls:7.64%
21
353
480
4657
11
138
490
4872
5
9
496
5001
—
6
13
494
4991
28
122
463
4793
39
341
407
4120
Psychiatry
26 [38004469]
26 [38004469]
-9.1e-01
-8.2e-01
—
—
3.0e-01
8.2e-01
5.3e-01
cases:2.00%
controls:4.83%
cases:1.00%
controls:2.24%
—
—
—
—
cases:1.00%
controls:0.74%
cases:5.50%
controls:2.50%
cases:6.95%
controls:4.19%
10
242
491
4768
5
112
496
4898
—
—
5
37
495
4967
27
123
464
4792
31
187
415
4274
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
7.9e-02
2.5e-01
—
—
—
3.4e-01
6.1e-01
cases:4.39%
controls:4.07%
cases:3.19%
controls:2.50%
—
—
—
—
—
—
cases:3.05%
controls:2.20%
cases:12.33%
controls:7.13%
22
204
479
4806
16
125
485
4885
—
—
—
15
108
476
4807
55
318
391
4143
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
5.1e-02
1.9e-01
1.3e-01
7.5e-01
5.7e-01
2.8e-01
3.8e-01
cases:88.22%
controls:87.68%
cases:85.43%
controls:82.89%
cases:50.10%
controls:46.91%
cases:4.39%
controls:2.12%
cases:60.00%
controls:45.78%
cases:87.98%
controls:84.74%
cases:96.86%
controls:95.49%
442
4393
59
617
428
4153
73
857
251
2350
250
2660
22
106
479
4904
300
2291
200
2713
432
4165
59
750
432
4260
14
201
zopiclone; oral
N05CF01 [21604654]
N05CF01 [21604654]
1.7e-01
4.2e-01
6.2e-01
—
4.9e-01
5.6e-01
3.4e-01
cases:10.18%
controls:8.76%
cases:7.98%
controls:5.39%
cases:2.59%
controls:1.42%
—
—
cases:2.20%
controls:1.36%
cases:9.57%
controls:5.68%
cases:13.68%
controls:10.11%
51
439
450
4571
40
270
461
4740
13
71
488
4939
—
11
68
489
4936
47
279
444
4636
61
451
385
4010
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
-1.0e-01
1.8e-01
1.8e-01
—
5.6e-01
5.1e-01
3.6e-01
cases:15.57%
controls:16.95%
cases:10.38%
controls:8.84%
cases:2.40%
controls:2.02%
—
—
cases:3.60%
controls:2.10%
cases:15.07%
controls:9.66%
cases:26.46%
controls:20.09%
78
849
423
4161
52
443
449
4567
12
101
489
4909
—
18
105
482
4899
74
475
417
4440
118
896
328
3565
Obstetrics / Gynecology
16 [38004461]
16 [38004461]
-4.5e-02
2.8e-01
—
—
3.4e-01
4.4e-01
4.2e-01
cases:17.96%
controls:18.64%
cases:7.98%
controls:6.15%
—
—
—
—
cases:1.40%
controls:1.00%
cases:8.96%
controls:5.96%
cases:22.20%
controls:15.76%
90
934
411
4076
40
308
461
4702
—
—
7
50
493
4954
44
293
447
4622
99
703
347
3758
Angiography of the heart and coronary arteries
81 [2002100125]
81 [2002100125]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
0
13
501
4997
—
—
—
—
—
0
15
446
4446
Multidisciplinary treatment meeting
WZC20 [2001310890]
WZC20 [2001310890]
—
1.7e+00
—
1.0e+50
1.0e+50
1.8e+00
—
—
—
cases:1.00%
controls:0.18%
—
—
cases:1.20%
controls:0.00%
cases:1.20%
controls:0.00%
cases:1.02%
controls:0.16%
—
—
—
5
9
496
5001
—
6
0
495
5010
6
0
494
5004
5
8
486
4907
—
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
5130-0 [3023420]
—
—
—
—
—
-1.0e+50
4.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:1.12%
controls:0.74%
—
—
—
—
—
0
20
491
4895
5
33
441
4428
Postmastectomy lymphoedema syndrome
I97.2 [45543249]
I97.2 [45543249]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
hydrocortisone and antiinfectives
S03CA04 [21605208]
S03CA04 [21605208]
2.0e-01
6.0e-01
—
—
—
—
4.7e-01
cases:2.00%
controls:1.64%
cases:1.20%
controls:0.66%
—
—
—
—
—
—
—
—
cases:2.91%
controls:1.84%
10
82
491
4928
6
33
495
4977
—
—
—
—
13
82
433
4379
Acute periodontitis UNS
K05.29 [2000502727]
K05.29 [2000502727]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
501
5004
—
—
—
—
—
—
Yersinia sp identified in Specimen by Organism specific culture
701-3 [3025468]
701-3 [3025468]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
501
5001
—
—
—
—
—
—
Vascular dementia, unspecified
F01.9 [45533058]
F01.9 [45533058]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
0
7
446
4454
Excision of axillary lymph nodes
PJD42 [2001309633]
PJD42 [2001309633]
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
cases:1.60%
controls:0.00%
cases:1.20%
controls:0.00%
—
—
—
—
—
—
—
8
0
493
5010
6
0
494
5004
—
—
Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid
22133-3 [3014973]
22133-3 [3014973]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
501
5002
—
—
—
—
—
—
Other and unspecified premature depolarization
I49.4 [45543180]
I49.4 [45543180]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
0
18
501
4992
0
5
501
5005
—
—
—
—
—
Shoulder symptom/complaint
L08 [2002000632]
L08 [2002000632]
0.0e+00
1.5e-01
—
—
—
-1.9e-02
3.5e-01
cases:2.40%
controls:2.40%
cases:1.00%
controls:0.86%
—
—
—
—
—
—
cases:1.02%
controls:1.04%
cases:5.38%
controls:3.86%
12
120
489
4890
5
43
496
4967
—
—
—
5
51
486
4864
24
172
422
4289
Cellulitis of other parts of limb
L03.1 [45586760]
L03.1 [45586760]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
0
6
501
5004
—
—
—
—
—
0
7
446
4454
Diverticular disease of intestine, part unspecified, without perforation or abscess
K57.9 [45543325]
K57.9 [45543325]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
9
501
5001
—
—
—
—
—
0
12
446
4449
Assessment of ability to drive and opinion
SPAT1282 [2001700383]
SPAT1282 [2001700383]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
0
7
446
4454
Influenza due to identified zoonotic or pandemic influenza virus
J09 [45755449]
J09 [45755449]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.18%
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
0
9
501
5001
0
5
501
5005
—
—
—
—
0
9
446
4452
Functional diarrhoea
K59.1 [45543327]
K59.1 [45543327]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
0
7
501
5003
—
—
—
0
6
491
4909
—
Acute tonsillitis, unspecified
J03.9 [45576942]
J03.9 [45576942]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
9
501
5001
—
—
—
—
—
0
14
446
4447
Maternal care due to uterine scar from previous surgery
O34.2 [45572805]
O34.2 [45572805]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
0
7
446
4454
Diabetes insipidus
E23.2 [45600651]
E23.2 [45600651]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Primary dysmenorrhoea
N94.4 [45606521]
N94.4 [45606521]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
—
timolol
S01ED01 [21603699]
S01ED01 [21603699]
1.5e-01
-2.2e-01
-1.0e+50
—
—
-2.5e-01
3.3e-01
cases:1.80%
controls:1.56%
cases:1.00%
controls:1.24%
cases:0.00%
controls:0.38%
—
—
—
—
cases:1.02%
controls:1.30%
cases:2.69%
controls:1.95%
9
78
492
4932
5
62
496
4948
0
19
501
4991
—
—
5
64
486
4851
12
87
434
4374
Heart failure
K77 [2002000604]
K77 [2002000604]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
6
446
4455
Repair of inguinal hernia using prosthetic material
JAB30 [2001304393]
JAB30 [2001304393]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
—
Psoriasis, unspecified
L40.9 [45533641]
L40.9 [45533641]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
501
5003
—
—
—
—
—
—
Cell count and differential, peritoneal fluid
67017004 [4281824]
67017004 [4281824]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
0
6
501
5004
—
—
—
—
—
lisinopril; oral
C09AA03 [21601787]
C09AA03 [21601787]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.22%
—
—
cases:0.00%
controls:0.20%
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.85%
—
0
29
501
4981
0
11
501
4999
—
0
10
500
4994
0
26
491
4889
0
38
446
4423
Severe hypofunction of sexual glands
121 [2001600120]
121 [2001600120]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
—
Emergency Medicine
93 [38004510]
93 [38004510]
-3.6e-01
2.2e-01
6.2e-02
—
8.9e-01
4.2e-01
-4.9e-02
cases:7.58%
controls:10.48%
cases:6.39%
controls:5.21%
cases:1.00%
controls:0.94%
—
—
cases:2.40%
controls:1.00%
cases:8.96%
controls:6.06%
cases:16.82%
controls:17.51%
38
525
463
4485
32
261
469
4749
5
47
496
4963
—
12
50
488
4954
44
298
447
4617
75
781
371
3680
Lower leg X-ray examination
NG4AA [2001308083]
NG4AA [2001308083]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
9
446
4452
Amniocentesis
MAA00 [2001306845]
MAA00 [2001306845]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
501
5003
—
—
—
—
—
—
metronidazole
D06BX01 [21602096]
D06BX01 [21602096]
2.9e-01
4.5e-01
-1.0e+50
—
—
—
4.4e-01
cases:2.79%
controls:2.10%
cases:1.00%
controls:0.64%
cases:0.00%
controls:0.10%
—
—
—
—
—
—
cases:2.91%
controls:1.91%
14
105
487
4905
5
32
496
4978
0
5
501
5005
—
—
—
13
85
433
4376
Trauma/injury NOS
A80 [2002000214]
A80 [2002000214]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Withdrawal symptoms caused by alcohol UNS
F10.39 [2000501687]
F10.39 [2000501687]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
—
Throat symptom/complaint
R21 [2002000891]
R21 [2002000891]
2.8e-01
—
—
—
—
—
-1.6e-01
cases:2.59%
controls:1.98%
—
—
—
—
—
—
—
—
—
—
cases:1.79%
controls:2.11%
13
99
488
4911
—
—
—
—
—
8
94
438
4367
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
-3.8e-01
—
—
—
—
6.8e-01
3.9e-02
cases:1.80%
controls:2.61%
—
—
—
—
—
—
—
—
cases:2.65%
controls:1.36%
cases:4.93%
controls:4.75%
9
131
492
4879
—
—
—
—
13
67
478
4848
22
212
424
4249
Aortic (valve) stenosis
I35.0 [45576869]
I35.0 [45576869]
—
—
—
—
—
—
8.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.57%
controls:0.65%
—
—
—
—
—
—
7
29
439
4432
Vertigo/dizziness
N17 [2002000728]
N17 [2002000728]
—
7.8e-01
-1.0e+50
—
—
—
3.5e-01
—
—
cases:1.00%
controls:0.46%
cases:0.00%
controls:0.12%
—
—
—
—
—
—
cases:2.47%
controls:1.75%
—
5
23
496
4987
0
6
501
5004
—
—
—
11
78
435
4383
flecainide; oral, parenteral
C01BC04 [21600266]
C01BC04 [21600266]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
0
6
500
4998
—
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
SMOKING-2-2-0 [2002330110]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.12%
controls:0.00%
—
—
—
—
—
—
5
0
441
4461
hydrocortisone
D07XA01 [21602180]
D07XA01 [21602180]
-9.7e-02
—
—
—
—
—
1.8e-01
cases:1.40%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:2.06%
7
77
494
4933
—
—
—
—
—
11
92
435
4369
Urinary tract infection, site not specified
N39.0 [45548665]
N39.0 [45548665]
—
—
—
—
—
—
3.5e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.69%
controls:2.60%
—
—
—
—
—
—
12
116
434
4345
losartan; oral
C09CA01 [21601824]
C09CA01 [21601824]
-1.4e-01
-6.5e-02
1.6e-01
—
1.1e-01
-5.2e-02
9.8e-02
cases:4.79%
controls:5.47%
cases:4.39%
controls:4.67%
cases:1.60%
controls:1.36%
—
—
cases:1.80%
controls:1.62%
cases:4.68%
controls:4.92%
cases:8.30%
controls:7.58%
24
274
477
4736
22
234
479
4776
8
68
493
4942
—
9
81
491
4923
23
242
468
4673
37
338
409
4123
Scoliosis X-ray examination
NA7EA [2001307086]
NA7EA [2001307086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
501
5003
—
—
—
—
—
—
Mycobacterium sp identified in Sputum by Organism specific culture
539-7 [3027544]
539-7 [3027544]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
9
446
4452
Total body bone isotope imaging
NK6AN [2001308473]
NK6AN [2001308473]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
501
5000
—
—
—
—
—
—
fexofenadine; oral
R06AX26 [21603525]
R06AX26 [21603525]
6.0e-01
—
—
—
—
—
4.5e-01
cases:1.20%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
cases:1.12%
controls:0.72%
6
33
495
4977
—
—
—
—
—
5
32
441
4429
Subacute thyrotoxicosis
E05.80 [2000501412]
E05.80 [2000501412]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Phosphatidylethanol [Mass/volume] in Blood
74661-0 [44816559]
74661-0 [44816559]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
cases:0.00%
controls:0.67%
0
6
501
5004
—
—
—
—
0
9
491
4906
0
30
446
4431
Cardiorespiratory global assessment
SPAT1081 [2001700182]
SPAT1081 [2001700182]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
0
5
491
4910
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
-1.9e-01
1.4e-01
—
—
—
-1.6e-01
2.3e-02
cases:6.59%
controls:7.88%
cases:4.99%
controls:4.35%
—
—
—
—
—
—
cases:4.48%
controls:5.23%
cases:12.33%
controls:12.08%
33
395
468
4615
25
218
476
4792
—
—
—
22
257
469
4658
55
539
391
3922
Femoral artery PTA
PE1AT [2001309252]
PE1AT [2001309252]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Malignant neoplasm: Overlapping lesion of breast
C50.8 [45532913]
C50.8 [45532913]
-1.0e+50
—
—
—
—
—
1.5e+00
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
cases:1.12%
controls:0.25%
0
5
501
5005
—
—
—
—
—
5
11
441
4450
Extensive colon CT
JF2BD [2001304826]
JF2BD [2001304826]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
6
446
4455
Ear pain/earache
H01 [2002000475]
H01 [2002000475]
3.4e-01
—
—
—
—
—
-1.3e-01
cases:1.40%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:1.35%
controls:1.52%
7
50
494
4960
—
—
—
—
—
6
68
440
4393
mirabegron; oral
G04BD12 [43534790]
G04BD12 [43534790]
-4.5e-01
5.8e-01
—
—
—
4.0e-01
1.1e-01
cases:1.00%
controls:1.56%
cases:1.60%
controls:0.90%
—
—
—
—
—
—
cases:1.63%
controls:1.10%
cases:2.47%
controls:2.22%
5
78
496
4932
8
45
493
4965
—
—
—
8
54
483
4861
11
99
435
4362
Other and unspecified skin changes
R23.8 [45573020]
R23.8 [45573020]
3.9e-01
—
—
—
—
2.9e-01
3.9e-01
cases:2.40%
controls:1.64%
—
—
—
—
—
—
—
—
cases:1.22%
controls:0.92%
cases:4.04%
controls:2.78%
12
82
489
4928
—
—
—
—
6
45
485
4870
18
124
428
4337
Spinal stenosis
M48.0 [45557888]
M48.0 [45557888]
-2.3e-01
—
—
—
—
5.7e-01
6.3e-02
cases:1.40%
controls:1.76%
—
—
—
—
—
—
—
—
cases:1.43%
controls:0.81%
cases:2.24%
controls:2.11%
7
88
494
4922
—
—
—
—
7
40
484
4875
10
94
436
4367
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
4548-4 [3004410]
-3.6e-01
-2.1e-01
—
—
-2.7e-01
-3.8e-01
-5.2e-02
cases:13.57%
controls:18.36%
cases:10.98%
controls:13.25%
—
—
—
—
cases:1.40%
controls:1.82%
cases:10.18%
controls:14.16%
cases:30.94%
controls:32.06%
68
920
433
4090
55
664
446
4346
—
—
7
91
493
4913
50
696
441
4219
138
1430
308
3031
Other chronic periodontitis
K05.38 [2000502732]
K05.38 [2000502732]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
0
9
501
5001
—
—
—
—
0
19
446
4442
Thyrotoxicosis, unspecified
E05.9 [45586131]
E05.9 [45586131]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.12%
controls:0.16%
—
—
—
—
—
—
5
7
441
4454
Fracture: other
L76 [2002000695]
L76 [2002000695]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
16
446
4445
Ethanol [Moles/volume] in Serum or Plasma
14719-9 [3020191]
14719-9 [3020191]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
6
446
4455
Extensive CT of neck arteries
PA6BD [2001308697]
PA6BD [2001308697]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
14
446
4447
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
Z03 [45552058]
—
1.8e+00
—
—
—
1.4e+00
8.6e-01
—
—
cases:1.00%
controls:0.16%
—
—
—
—
—
—
cases:1.02%
controls:0.26%
cases:1.57%
controls:0.67%
—
5
8
496
5002
—
—
—
5
13
486
4902
7
30
439
4431
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
-1.7e-01
-2.2e-01
—
—
2.4e-01
1.5e-01
1.1e-01
cases:10.18%
controls:11.86%
cases:5.19%
controls:6.41%
—
—
—
—
cases:1.60%
controls:1.26%
cases:8.15%
controls:7.12%
cases:19.96%
controls:18.22%
51
594
450
4416
26
321
475
4689
—
—
8
63
492
4941
40
350
451
4565
89
813
357
3648
Foot/toe symptom/complaint
L17 [2002000641]
L17 [2002000641]
1.8e-01
6.6e-02
-1.0e+50
—
-1.0e+50
1.6e-02
-1.4e-01
cases:3.79%
controls:3.19%
cases:1.60%
controls:1.50%
cases:0.00%
controls:0.20%
—
—
cases:0.00%
controls:0.24%
cases:1.43%
controls:1.40%
cases:4.48%
controls:5.13%
19
160
482
4850
8
75
493
4935
0
10
501
5000
—
0
12
500
4992
7
69
484
4846
20
229
426
4232
felodipine; oral
C08CA02 [21601748]
C08CA02 [21601748]
1.8e-01
6.4e-01
—
—
9.7e-01
5.2e-01
1.5e-01
cases:2.00%
controls:1.68%
cases:2.40%
controls:1.28%
—
—
—
—
cases:1.00%
controls:0.38%
cases:2.24%
controls:1.34%
cases:2.47%
controls:2.13%
10
84
491
4926
12
64
489
4946
—
—
5
19
495
4985
11
66
480
4849
11
95
435
4366
Vesical tenesmus
R30.1 [45602017]
R30.1 [45602017]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
9
446
4452
JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method
80187-8 [21494670]
80187-8 [21494670]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
501
5003
—
—
—
—
—
—
Nuclear Ab [Presence] in Serum
8061-4 [3004616]
8061-4 [3004616]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
cases:0.00%
controls:0.20%
—
—
—
—
—
0
5
491
4910
0
9
446
4452
Examination and observation for other specified reasons
Z04.8 [45552063]
Z04.8 [45552063]
0.0e+00
8.3e-01
—
—
—
1.2e+00
6.3e-01
cases:1.20%
controls:1.20%
cases:1.00%
controls:0.44%
—
—
—
—
—
—
cases:1.22%
controls:0.37%
cases:3.14%
controls:1.70%
6
60
495
4950
5
22
496
4988
—
—
—
6
18
485
4897
14
76
432
4385
rofecoxib; oral
M01AH02 [21603993]
M01AH02 [21603993]
-5.9e-02
—
—
—
—
—
9.2e-01
cases:1.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
cases:1.35%
controls:0.54%
5
53
496
4957
—
—
—
—
—
6
24
440
4437
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
77147-7 [46236952]
—
—
—
—
—
-1.0e+50
-2.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:1.12%
controls:1.39%
—
—
—
—
—
0
16
491
4899
5
62
441
4399
Special examination, unspecified
Z01.9 [45576123]
Z01.9 [45576123]
—
-1.0e+50
—
—
—
-1.0e+50
8.3e-01
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:1.12%
controls:0.49%
—
0
5
501
5005
—
—
—
0
10
491
4905
5
22
441
4439
Lumbar spine extensive MRI examination with high intensity magnet
NA3CG [2001307039]
NA3CG [2001307039]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
20
501
4990
—
—
—
—
—
—
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
-4.0e-01
4.9e-01
—
—
—
—
4.3e-01
cases:1.00%
controls:1.48%
cases:1.40%
controls:0.86%
—
—
—
—
—
—
—
—
cases:4.48%
controls:2.96%
5
74
496
4936
7
43
494
4967
—
—
—
—
20
132
426
4329
Central perforation of tympanic membrane
H72.0 [45538342]
H72.0 [45538342]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
0
7
501
5003
—
—
—
—
—
0
5
446
4456
Pain in throat
R07.0 [45592406]
R07.0 [45592406]
5.5e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:1.00%
controls:0.58%
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
5
29
496
4981
0
7
501
5003
—
—
—
0
6
491
4909
—
Periodic check-up in occupational healthcare
SPAT1368 [2001700469]
SPAT1368 [2001700469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
0
7
446
4454
Pneumonia, organism unspecified
J18 [45548107]
J18 [45548107]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Secondary malignant neoplasm of other specified sites
C79.8 [45547524]
C79.8 [45547524]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
1.7e+00
cases:0.00%
controls:0.10%
cases:0.00%
controls:0.12%
—
—
—
—
—
—
cases:0.00%
controls:0.10%
cases:1.12%
controls:0.20%
0
5
501
5005
0
6
501
5004
—
—
—
0
5
491
4910
5
9
441
4452
infliximab; parenteral
L04AB02 [21603909]
L04AB02 [21603909]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
alendronic acid and colecalciferol; oral
M05BB03 [21604160]
M05BB03 [21604160]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
0
10
501
5000
—
—
—
—
0
22
446
4439
Sleep disturbance
P06 [2002000803]
P06 [2002000803]
2.5e-01
—
—
—
—
—
2.9e-01
cases:1.20%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
cases:2.24%
controls:1.68%
6
47
495
4963
—
—
—
—
—
10
75
436
4386
Cocaine [Presence] in Urine
3397-7 [3016879]
3397-7 [3016879]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
16
446
4445
Nerve root and plexus compressions in intervertebral disc disorders
G55.1 [45566889]
G55.1 [45566889]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
—
Presbyopia
H52.4 [45605710]
H52.4 [45605710]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
Irregular menstruation, unspecified
N92.6 [45539075]
N92.6 [45539075]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
0
7
501
5003
—
—
—
—
0
17
446
4444
Podiatric therapy
R4180 [2001310242]
R4180 [2001310242]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Plantar fascial fibromatosis
M72.2 [45553265]
M72.2 [45553265]
3.6e-01
-1.0e+50
—
—
—
—
—
cases:1.00%
controls:0.70%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
5
35
496
4975
0
14
501
4996
—
—
—
—
—
Protein [Mass] in Urine collected for unspecified duration
32551-4 [3017817]
32551-4 [3017817]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Other disorders resulting from impaired renal tubular function
N25.8 [45582397]
N25.8 [45582397]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
—
CT of face
AA3AD [2001300130]
AA3AD [2001300130]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Implant borne crown
SPC20 [2001310515]
SPC20 [2001310515]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
—
oxycodone and naloxone; oral
N02AA55 [21604265]
N02AA55 [21604265]
—
3.3e-01
—
—
-1.0e+50
—
-1.9e-01
—
—
cases:1.00%
controls:0.72%
—
—
—
—
cases:0.00%
controls:0.10%
—
—
cases:2.69%
controls:3.23%
—
5
36
496
4974
—
—
0
5
500
4999
—
12
144
434
4317
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
SDE04 [2001310352]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
0
16
491
4899
—
PEF monitoring instruction
SPAT1058 [2001700159]
SPAT1058 [2001700159]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
0
12
501
4998
—
—
—
0
12
491
4903
—
Migraine with aura [classical migraine]
G43.1 [45562086]
G43.1 [45562086]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
0
13
501
4997
—
—
—
0
16
491
4899
—
mometasone, combinations
R01AD59 [947911]
R01AD59 [947911]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
—
0
7
501
5003
—
—
—
—
—
Nausea
D09 [2002000308]
D09 [2002000308]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
12
446
4449
Superficial injury of scalp
S00.0 [45548998]
S00.0 [45548998]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
0
5
501
5005
—
—
—
—
—
0
15
446
4446
Other specified pleural conditions
J94.8 [45567278]
J94.8 [45567278]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
501
5004
—
—
—
—
—
—
mercaptopurine
L01BB02 [21601428]
L01BB02 [21601428]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
Chest pain NOS
A11 [2002000152]
A11 [2002000152]
—
—
—
—
—
-1.0e+50
4.5e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
cases:1.57%
controls:1.01%
—
—
—
—
—
0
13
491
4902
7
45
439
4416
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
1.5e-01
3.8e-01
—
—
—
1.1e-01
3.1e-01
cases:2.79%
controls:2.42%
cases:1.80%
controls:1.24%
—
—
—
—
—
—
cases:1.22%
controls:1.10%
cases:5.38%
controls:3.99%
14
121
487
4889
9
62
492
4948
—
—
—
6
54
485
4861
24
178
422
4283
Shoulder extensive X-ray examination without contrast
NB1BA [2001307228]
NB1BA [2001307228]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
cases:0.00%
controls:0.31%
0
5
501
5005
—
—
—
—
0
5
491
4910
0
14
446
4447
Mild cervical dysplasia
N87.0 [45567868]
N87.0 [45567868]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
0
6
491
4909
—
clidinium and psycholeptics
A03CA02 [21600204]
A03CA02 [21600204]
5.0e-01
—
—
—
—
—
1.1e-01
cases:1.80%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
cases:1.57%
controls:1.41%
9
55
492
4955
—
—
—
—
—
7
63
439
4398
Spasmodic torticollis
G24.3 [45600774]
G24.3 [45600774]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
8
446
4453
Single shot through catheter
WX600 [2001310811]
WX600 [2001310811]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
501
5002
—
—
—
—
—
—
Other local infections of skin and subcutaneous tissue
L08 [45596365]
L08 [45596365]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
6
446
4455
Urinary tract cathetrisation with X-ray guidance
KH1BT [2001305794]
KH1BT [2001305794]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Intraoperative use of conventional X-ray imaging
ZXM10 [2001311446]
ZXM10 [2001311446]
—
—
—
—
—
-1.0e+50
8.4e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:1.35%
controls:0.58%
—
—
—
—
—
0
8
491
4907
6
26
440
4435
Cardiovascular stress test using bicycle ergometer
26046004 [4094501]
26046004 [4094501]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
0
7
491
4908
—
Grinding of a single crown and bridge pillar or a single post and crown
SPA30 [2001310471]
SPA30 [2001310471]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
6
446
4455
Other specified medical care
Z51.88 [2000503765]
Z51.88 [2000503765]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
0
6
501
5004
—
—
—
—
—
0
8
446
4453
General Practice
1 [38004446]
1 [38004446]
-1.5e-01
2.7e-01
—
—
—
-1.1e-01
2.3e-01
cases:9.78%
controls:11.18%
cases:5.99%
controls:4.65%
—
—
—
—
—
—
cases:4.48%
controls:4.98%
cases:16.37%
controls:13.43%
49
560
452
4450
30
233
471
4777
—
—
—
22
245
469
4670
73
599
373
3862
Albumin [Mass/volume] in Cerebral spinal fluid
1746-7 [3024474]
1746-7 [3024474]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
501
5004
—
—
—
—
—
—
sodium fluoride; oral
A01AA01 [21600005]
A01AA01 [21600005]
7.9e-01
—
—
—
—
—
—
cases:1.40%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
7
32
494
4978
—
—
—
—
—
—
Other difficulties with micturition
R39.1 [45534441]
R39.1 [45534441]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
0
8
501
5002
—
—
—
—
—
0
9
446
4452
Dry mouth, unspecified
R68.2 [45558479]
R68.2 [45558479]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
0
5
491
4910
—
Multiple fractures of ribs
S22.4 [45582958]
S22.4 [45582958]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
—
Simple partial seizures
G40.10 [2000502135]
G40.10 [2000502135]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
0
5
446
4456
Potassium [Moles/volume] in Arterial blood
32713-0 [3043409]
32713-0 [3043409]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
0
17
501
4993
0
7
501
5003
—
—
—
—
—
Osteoarthrosis other
L91 [2002000710]
L91 [2002000710]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
501
4996
—
—
—
—
—
—
One-surface restoration
SFA10 [2001310358]
SFA10 [2001310358]
-2.1e-01
8.6e-02
—
—
—
-5.0e-02
-6.8e-02
cases:9.38%
controls:11.34%
cases:4.79%
controls:4.41%
—
—
—
—
—
—
cases:4.07%
controls:4.27%
cases:13.68%
controls:14.50%
47
568
454
4442
24
221
477
4789
—
—
—
20
210
471
4705
61
647
385
3814
Acute pain
R52.0 [45573031]
R52.0 [45573031]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.12%
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
0
6
501
5004
0
5
501
5005
—
—
—
—
—
prochlorperazine; oral, parenteral, rectal
N05AB04 [21604503]
N05AB04 [21604503]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
0
5
501
5005
—
—
—
—
—
Bradycardia, unspecified
R00.1 [45539313]
R00.1 [45539313]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
7
501
5003
—
—
—
—
—
0
16
446
4445
Other psoriatic arthropathies
M07.3 [45591706]
M07.3 [45591706]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
501
5004
—
—
—
—
—
—
Benign lipomatous neoplasm
D17 [45537894]
D17 [45537894]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
6
446
4455
Myopia
H52.1 [45533352]
H52.1 [45533352]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
18
446
4443
Operative extraction of tooth
EBA10 [2001301925]
EBA10 [2001301925]
4.3e-01
-1.0e+50
—
—
—
—
—
cases:1.20%
controls:0.78%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
6
39
495
4971
0
14
501
4996
—
—
—
—
—
vilanterol and fluticasone furoate
R03AK10 [43534841]
R03AK10 [43534841]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
0
12
501
4998
—
0
8
500
4996
—
—
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
MA1AE [2001306827]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
6
446
4455
Application of soft bandage
SPAT1211 [2001700312]
SPAT1211 [2001700312]
—
-1.0e+50
—
—
—
1.4e+00
7.5e-01
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
cases:1.02%
controls:0.26%
cases:1.79%
controls:0.85%
—
0
13
501
4997
—
—
—
5
13
486
4902
8
38
438
4423
Rheumatism, unspecified
M79.0 [45567658]
M79.0 [45567658]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.54%
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
0
27
501
4983
0
9
501
5001
—
—
—
—
—
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
F00.10*G30.1 [2000501573]
F00.10*G30.1 [2000501573]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.20%
cases:0.00%
controls:0.18%
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
0
10
501
5000
0
9
501
5001
—
—
—
0
11
491
4904
—
Urethritis
U72 [2002001192]
U72 [2002001192]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
9
446
4452
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
274
1932
1.91
11.46
3.7
3.4
2.38
2.37
mmol/l
1.08
258
1744
99
488
2.28
11.14
3.3
3.5
—
—
—
0
0
432
3705
2.15
8.52
10.1
8.1
75.17
79.57
u/l
1.86
405
3498
85
439
2.13
8.40
4.5
3.6
1.24
1.24
mmol/l
0.20
66
374
284
2220
1.64
6.79
2.4
2.6
—
—
estimate
—
0
0
321
2633
1.60
5.93
7.6
6.2
9.89
10.43
umol/l
0.66
304
2499
321
2752
1.46
3.95
10.1
9.7
3.54
3.96
e9/l
4.09
288
2395
20
442
0.43
3.55
2.3
2.4
3.82
4.26
kpa
0.89
20
432
27
523
0.49
3.36
2.5
2.8
6.27
5.85
kpa
1.70
27
512
26
504
0.49
3.24
2.5
2.8
2.43
2.31
mmol/l
0.09
26
438
13
327
0.38
3.15
2.5
2.4
124.69
126.76
g/l
0.17
13
320
11
30
3.72
3.10
1.1
1.1
—
—
—
0
0
136
1714
0.72
2.77
3.9
3.9
8.30
6.15
mg/mmol
0.23
65
963
137
1723
0.72
2.75
3.2
3.2
5.82
6.20
mmol/l
0.65
102
1439
29
155
1.92
2.67
1.3
1.2
—
—
—
0
0
197
2329
0.75
2.59
2.1
2.2
100.82
98.92
pmol/l
0.18
87
1099
0
67
0.00
2.40
0.0
1.0
—
—
—
0
0
461
4379
1.61
2.37
19.5
16.5
77.44
76.39
ml/min/173m2
0.64
434
4084
398
3678
1.39
2.35
22.6
20.9
13.65
13.75
%
0.90
390
3626
20
98
2.08
2.35
2.7
2.4
16.30
15.71
%
0.36
20
98
87
1150
0.71
2.29
3.6
4.7
1.01
1.02
kg/l
1.55
56
771
144
1157
1.34
2.26
2.7
2.8
2.47
2.47
mmol/l
0.04
136
1045
38
593
0.61
2.26
4.7
6.9
—
—
—
0
0
106
815
1.38
2.20
2.5
2.8
0.84
0.81
mmol/l
1.71
97
756
275
2436
1.28
2.05
5.5
5.6
1.22
1.22
mmol/l
0.05
245
2229
15
292
0.50
1.95
2.2
2.8
24.99
24.68
mmol/l
0.19
15
287
80
611
1.37
1.74
5.1
4.2
4.19
10.48
ug/l
2.34
67
503
12
240
0.49
1.71
2.7
2.6
26.72
25.52
mmol/l
0.55
12
234
20
112
1.82
1.67
2.7
2.5
10.15
7.44
pmol/l
0.29
20
112
295
2677
1.25
1.64
6.6
6.5
1.22
1.22
mmol/l
0.47
227
2302
8
171
0.46
1.61
2.0
1.9
682.13
167.23
ug/l
—
8
159
71
543
1.36
1.54
2.6
2.3
9.96
6.87
umol/l
0.33
56
480
5
15
3.36
1.52
1.2
1.3
—
—
—
0
0
23
139
1.69
1.51
1.7
2.4
—
—
—
0
0
8
170
0.46
1.49
1.6
1.5
—
—
—
0
0
125
1042
1.27
1.46
1.5
1.4
—
—
—
0
0
46
333
1.42
1.39
2.3
2.7
27.76
26.40
au/ml
—
5
27
57
431
1.36
1.34
2.5
3.7
45.24
92.35
u/ml
0.67
52
417
140
1621
0.81
1.31
2.2
2.1
142.89
147.47
u/l
0.07
128
1541
31
442
0.68
1.26
4.7
5.6
1.13
1.33
mmol/l
1.00
31
434
49
637
0.74
1.17
5.8
5.1
34.45
34.19
%
0.06
29
386
76
613
1.28
1.16
3.1
4.0
1.06
1.05
mmol/l
0.09
66
549
135
1169
1.21
1.10
2.1
2.3
—
—
—
0
0
30
416
0.70
1.07
2.9
2.7
64.08
64.43
ml/min/173m2
0.01
13
174
73
886
0.79
1.04
2.0
1.7
1152.19
1221.44
nmol/l
0.21
43
644
137
1558
0.83
1.03
1.6
1.7
20.42
21.66
nmol/l
0.49
106
1289
247
2272
1.17
1.00
14.8
13.4
1.23
1.21
inr
0.24
216
1858
22
148
1.51
0.99
2.2
2.8
24.65
25.48
mmol/l
0.66
22
148
7
135
0.51
0.99
1.3
1.7
—
—
—
0
0
5
23
2.19
0.98
1.0
1.0
—
—
—
0
0
0
29
0.00
0.98
0.0
1.9
—
49.10
—
0
29
10
171
0.58
0.93
1.0
1.3
—
—
—
0
0
30
219
1.39
0.92
1.1
1.3
—
—
—
0
0
265
2464
1.16
0.90
2.6
2.5
82.83
81.46
nmol/l
0.37
238
2199
6
29
2.08
0.89
1.5
1.2
6.67
16.52
u/l
—
6
23
6
30
2.01
0.87
1.5
1.2
45.33
76.04
u/l
—
6
25
90
769
1.21
0.85
2.4
3.2
2.26
4.14
e6/l
1.57
42
345
19
129
1.49
0.84
3.8
2.9
1.89
1.74
index
—
9
61
445
4556
0.80
0.81
6.2
6.4
2.82
2.74
mmol/l
1.18
380
4178
0
26
0.00
0.78
0.0
3.8
—
202.58
—
0
26
376
3607
1.17
0.78
4.4
4.8
13.36
13.56
mm/h
0.09
331
3338
14
91
1.55
0.76
1.3
1.3
—
—
—
0
0
244
2279
1.14
0.73
4.4
4.3
36.35
35.51
g/l
1.70
221
2136
7
39
1.81
0.72
1.1
1.1
—
—
—
0
0
34
265
1.30
0.72
2.3
4.0
1.02
1.02
ratio
0.18
28
247
7
40
1.76
0.71
1.0
1.1
—
—
—
0
0
7
40
1.76
0.71
1.0
1.1
—
—
—
0
0
32
408
0.77
0.71
1.6
2.3
0.38
0.63
e6/l
0.44
32
388
5
26
1.93
0.71
1.2
1.7
—
—
—
0
0
474
4654
1.30
0.70
19.1
19.6
139.84
139.76
mmol/l
0.30
456
4555
114
1274
0.86
0.68
2.3
2.3
2.50
3.03
mg/l
1.55
93
1078
7
43
1.64
0.67
1.0
1.1
—
—
—
0
0
7
43
1.64
0.67
1.4
1.6
—
—
—
0
0
474
4660
1.28
0.63
19.3
19.7
3.93
3.95
mmol/l
0.59
454
4552
133
1205
1.14
0.63
3.3
3.7
92.55
93.32
%
0.11
128
1177
15
210
0.71
0.62
1.1
2.1
1.46
1.59
g/l
—
10
186
8
53
1.52
0.58
1.4
1.2
59.12
54.25
u/l
—
8
46
426
4354
0.86
0.56
5.9
6.8
38.78
39.42
mmol/mol
0.98
369
4040
438
4467
0.85
0.55
5.4
5.6
5.86
5.92
mmol/l
0.49
358
4068
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
16
116
1.39
0.55
3.9
2.5
0.29
0.40
iu/ml
—
10
74
6
38
1.59
0.54
1.0
1.1
—
—
—
0
0
415
4245
0.87
0.52
4.3
4.5
1.25
1.26
mmol/l
0.19
340
3834
19
247
0.76
0.51
1.1
1.1
—
—
—
0
0
97
1071
0.88
0.49
1.7
1.7
456.17
12717225.61
pmol/l
0.80
63
865
11
155
0.70
0.49
1.4
1.9
2.94
2.39
mg/l
0.13
11
124
7
110
0.63
0.49
6.1
3.9
71.29
2296.62
u/ml
—
7
105
22
277
0.78
0.48
1.6
1.9
3.71
3.48
mmol/l
0.54
15
208
7
47
1.50
0.47
1.0
1.1
—
—
—
0
0
89
985
0.88
0.47
3.5
4.1
318.72
234.91
ng/l
0.15
69
779
7
48
1.46
0.47
1.3
1.3
—
223.13
u/l
—
0
15
99
1087
0.89
0.46
2.4
2.7
5.52
7.77
e6/l
0.50
86
1010
19
241
0.78
0.44
1.2
1.3
—
—
—
0
0
6
92
0.65
0.42
1.2
1.3
—
—
—
0
0
6
92
0.65
0.42
1.2
1.3
—
—
—
0
0
5
32
1.57
0.42
1.4
1.4
—
—
—
0
0
31
368
0.83
0.41
1.9
2.1
3.38
3.23
ratio
0.45
24
303
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
24
195
1.24
0.41
2.8
2.5
0.18
0.85
g/l
1.24
19
169
94
859
1.12
0.40
2.4
3.0
1.09
1.35
e6/l
0.45
46
443
479
4737
1.22
0.40
23.9
22.2
69.62
70.81
umol/l
0.68
470
4674
0
18
0.00
0.40
0.0
1.2
—
9.87
—
0
18
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
5
35
1.43
0.39
1.4
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.6
—
—
—
0
0
452
4452
1.15
0.39
17.1
16.5
19.77
22.47
mg/l
1.12
370
3660
397
3883
1.10
0.39
5.3
5.0
15.07
14.97
pmol/l
0.33
343
3559
439
4458
0.88
0.39
5.2
5.4
1.63
1.61
mmol/l
0.59
371
4075
240
2501
0.92
0.38
2.9
2.7
—
—
—
0
0
12
158
0.75
0.37
2.1
1.8
—
—
—
0
0
5
37
1.35
0.37
1.4
1.3
—
—
—
0
0
11
81
1.37
0.36
1.3
1.7
—
—
—
0
0
15
117
1.29
0.35
1.9
2.2
173.73
198.41
%
0.62
15
111
35
404
0.86
0.35
1.4
1.5
—
—
—
0
0
55
491
1.13
0.35
2.3
2.3
30.18
37.41
u/l
1.26
45
397
442
4482
0.89
0.35
5.2
5.5
4.87
4.81
mmol/l
0.56
376
4122
50
446
1.13
0.33
2.3
2.8
68.13
67.08
g/l
0.45
43
407
17
207
0.82
0.30
1.3
1.6
—
—
—
0
0
7
54
1.30
0.30
1.1
1.1
—
—
—
0
0
50
555
0.89
0.30
5.2
6.4
1.69
1.42
mmol/l
0.21
41
473
299
2906
1.07
0.30
3.1
3.1
51.86
46.08
u/l
0.25
263
2687
53
479
1.12
0.29
2.1
2.0
0.22
0.21
g/l
0.86
45
449
8
64
1.25
0.27
1.4
1.6
—
—
—
0
0
8
65
1.23
0.27
1.4
1.6
—
—
—
0
0
212
2197
0.94
0.27
2.8
3.0
96.43
100.34
ug/l
0.18
188
2017
14
170
0.82
0.25
2.0
1.8
—
—
—
0
0
9
74
1.22
0.25
1.2
1.4
—
—
—
0
0
149
1557
0.94
0.24
2.1
2.4
53.15
61.86
u/l
1.03
128
1421
6
82
0.73
0.24
1.3
1.3
0.47
22.75
nmol/l
—
6
77
25
218
1.15
0.23
3.4
2.7
226.10
1030.59
u/ml
0.65
20
190
185
1918
0.94
0.23
4.1
4.5
0.08
0.05
estimate
0.19
48
421
5
39
1.28
0.23
1.0
1.0
—
—
—
0
0
113
1188
0.94
0.22
2.2
2.6
315.43
321.64
umol/l
0.23
91
1025
36
324
1.12
0.22
1.2
1.2
156.20
118.22
u/ml
0.24
30
302
481
4777
1.15
0.22
26.9
25.6
91.45
91.36
fl
0.16
468
4718
5
41
1.22
0.22
1.0
1.4
—
—
—
0
0
162
1559
1.06
0.21
3.3
2.8
27.92
31.22
u/l
0.66
153
1472
0
11
0.00
0.21
0.0
1.0
—
23.08
—
0
11
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
7.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
12
98
1.23
0.21
1.1
1.1
—
—
—
0
0
8
101
0.79
0.21
1.0
1.2
1.52
1.68
g/l
—
8
101
481
4778
1.14
0.21
27.2
26.0
39.49
39.36
%
0.29
468
4718
481
4778
1.14
0.21
27.0
25.7
255.00
260.51
e9/l
1.30
468
4681
481
4778
1.14
0.21
27.0
25.7
4.36
4.37
e12/l
0.15
465
4665
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
481
4779
1.14
0.20
27.1
25.9
130.56
130.98
g/l
0.32
468
4719
16
136
1.18
0.20
1.1
1.3
—
9.67
—
0
10
0
14
0.00
0.20
0.0
2.5
—
2.68
—
0
5
9
113
0.79
0.20
1.1
1.6
—
—
—
0
0
15
176
0.85
0.20
1.6
1.7
—
—
—
0
0
118
1128
1.06
0.20
1.6
1.7
1.65
1.14
mg/l
0.37
95
898
141
1359
1.05
0.18
2.9
3.3
0.47
0.44
e6/l
0.05
92
993
7
60
1.17
0.18
1.1
1.3
—
—
—
0
0
215
2095
1.05
0.17
2.0
1.9
1.28
1.32
mmol/l
0.45
145
1733
7
61
1.15
0.17
1.1
1.3
—
—
—
0
0
7
61
1.15
0.17
1.1
1.3
—
—
—
0
0
7
62
1.13
0.17
1.0
1.0
—
—
—
0
0
138
1331
1.05
0.17
4.0
4.0
0.04
0.01
estimate
0.42
50
421
11
131
0.84
0.17
1.4
1.3
—
—
—
0
0
15
129
1.17
0.17
1.4
1.9
92.80
96.92
%
0.22
15
124
473
4700
1.10
0.17
14.8
12.9
24.67
23.00
u/l
0.50
451
4547
69
729
0.94
0.16
1.4
1.4
—
—
—
0
0
40
370
1.09
0.16
1.4
1.6
—
—
—
0
0
156
1609
0.96
0.16
2.9
3.0
949.58
1042.41
ng/l
0.23
132
1385
34
312
1.10
0.16
2.3
3.2
4.47
4.44
pmol/l
0.04
27
274
34
368
0.92
0.15
1.7
1.4
1.25
1.41
%
1.07
28
315
7
88
0.79
0.14
1.3
1.2
—
97.14
—
0
7
8
97
0.82
0.14
1.4
1.4
—
—
—
0
0
33
356
0.92
0.13
1.2
1.2
99.00
155.26
u/ml
0.72
13
143
9
107
0.84
0.13
1.3
1.2
1.08
0.93
g/l
—
9
107
94
974
0.96
0.12
1.3
1.3
18.67
12.66
u/ml
0.21
31
355
184
1880
0.97
0.12
3.8
3.8
26.26
77.96
ng/l
0.87
144
1372
260
2640
0.97
0.11
4.0
4.6
0.00
0.02
estimate
1.23
56
524
19
172
1.11
0.11
1.2
1.3
—
2.07
—
0
20
101
1043
0.96
0.11
1.3
1.3
45.43
33.61
iu/ml
0.21
27
336
67
643
1.05
0.11
1.7
1.9
—
—
—
0
0
34
320
1.07
0.10
2.0
1.8
—
—
—
0
0
5
45
1.11
0.10
1.2
1.2
—
—
—
0
0
5
45
1.11
0.10
1.2
1.0
—
—
—
0
0
5
47
1.06
0.09
1.4
1.6
—
—
—
0
0
79
816
0.96
0.09
2.5
2.3
12.12
12.31
umol/l
0.09
68
761
6
57
1.05
0.08
2.2
1.5
4.08
71.64
u/ml
—
6
57
5
60
0.83
0.08
1.2
1.2
—
—
—
0
0
7
64
1.10
0.08
1.1
1.3
—
—
—
0
0
7
64
1.10
0.08
1.0
1.3
—
—
—
0
0
7
64
1.10
0.08
1.1
1.3
—
—
—
0
0
17
184
0.92
0.07
1.2
1.5
—
—
—
0
0
10
111
0.90
0.06
1.4
1.5
—
—
—
0
0
24
253
0.95
0.05
1.4
1.5
—
—
—
0
0
13
141
0.92
0.05
2.5
1.4
—
—
—
0
0
73
713
1.03
0.05
2.2
2.3
22.13
21.07
%
0.23
62
667
14
151
0.93
0.05
1.7
1.8
4.45
3.70
iu/l
—
5
59
78
763
1.03
0.05
2.3
2.3
2.23
2.37
g/l
1.40
65
707
143
1450
0.98
0.05
3.9
4.6
0.00
0.00
estimate
0.50
56
506
16
150
1.07
0.04
1.1
1.2
—
—
—
0
0
179
1808
0.98
0.04
3.6
4.2
122.74
111.29
e6/l
0.06
117
1259
15
160
0.94
0.04
1.1
1.2
—
—
—
0
0
437
4384
0.98
0.04
6.4
6.3
1.84
1.93
mu/l
1.11
389
4040
60
613
0.98
0.04
1.7
1.9
—
—
—
0
0
15
141
1.07
0.03
1.1
1.3
—
—
—
0
0
15
159
0.94
0.03
1.1
1.2
—
—
—
0
0
172
1707
1.01
0.02
2.8
3.4
—
—
—
0
0
281
2822
0.99
0.02
4.0
4.5
6.48
6.60
mmol/l
0.55
273
2682
85
840
1.01
0.02
1.9
1.9
—
—
—
0
0
24
232
1.04
0.02
2.7
3.2
1.89
2.31
mmol/l
0.26
16
181
50
491
1.02
0.02
2.5
3.1
63.54
77.49
ng/l
1.10
37
431
117
1160
1.01
0.02
1.2
1.3
0.59
1.90
u/ml
1.91
28
296
11
117
0.94
0.01
1.4
1.6
—
—
—
0
0
258
2588
0.99
0.01
4.0
4.5
0.00
0.00
estimate
-0.00
55
525
10
94
1.07
0.01
1.9
1.3
—
—
—
0
0
14
136
1.03
0.00
2.0
1.6
—
—
—
0
0
27
275
0.98
0.00
2.9
3.3
5.03
5.23
kpa
0.86
27
267
10
97
1.03
0.00
1.3
1.4
—
—
—
0
0
10
103
0.97
0.00
1.5
1.6
—
—
—
0
0
17
167
1.02
0.00
1.1
1.3
292.79
297.39
ug/g
—
8
96
16
158
1.01
0.00
4.8
3.6
1.27
2.35
ratio
1.50
11
94
48
477
1.01
0.00
2.0
2.0
372.84
381.94
nmol/l
0.12
43
444
12
121
0.99
0.00
1.3
1.6
—
—
—
0
0
158
1582
1.00
0.00
2.8
3.4
31.27
54.46
e6/l
0.65
107
1208
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
2.4
—
0.75
—
0
8
0
6
0.00
0.00
0.0
1.3
—
50.03
—
0
6
0
8
0.00
0.00
0.0
1.1
—
7.77
—
0
8
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
7.69
—
0
6
5
57
0.88
0.00
5.4
5.3
12.26
13.85
mg/l
—
5
51
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
9.25
—
0
8
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
78
0.90
-0.00
1.4
1.5
—
—
—
0
0
8
83
0.96
-0.00
1.6
1.5
—
—
—
0
0
261
2610
1.00
-0.00
3.9
4.5
0.00
6.37
estimate
0.80
60
550
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
97.40
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
15.40
—
0
5
0
9
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
6.00
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_BREAST_NOS – Carcinoma in situ of breast, other/unspecified
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).